sugar conjugate

Complex carbohydrates with a GlcNAc-Gal-Sia linker improve ADCs by ensuring consistent drug-to-antibody ratios and solubility, enhancing in vivo efficacy and treatment tolerability.

JP7948919B2Active Publication Date: 2026-11-11UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023523196
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-16
Filing Date
2021-10-14
Publication Date
2026-11-11
Estimated Expiration
2041-10-14

AI Technical Summary

Technical Problem

Existing methods for producing antibody-drug conjugates (ADCs) face challenges in achieving site-specific conjugation, leading to heterogeneity in glycan structures and undesirable drug-to-antibody ratios, which affect the efficacy and safety of cancer treatment.

Method used

The development of complex carbohydrates with a trisaccharide moiety (GlcNAc-Gal-Sia) as an oligosaccharide linker, utilizing galactosyltransferases and sialyltransferases to efficiently conjugate cytotoxic drugs to antibodies, ensuring consistent drug-to-antibody ratios and improved solubility and conjugation kinetics.

Benefits of technology

The trisaccharide-linked ADCs demonstrate enhanced in vivo efficacy, improved treatment tolerability, and consistent drug delivery, addressing the issues of heterogeneity and toxicity in conventional ADCs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007948919000125
    Figure 0007948919000125
  • Figure 0007948919000126
    Figure 0007948919000126
  • Figure 0007948919000127
    Figure 0007948919000127
Patent Text Reader

Abstract

Provided herein are glycoconjugates comprising a cell-binding agent, such as an antibody, and conjugated to a payload, such as a drug, which is conjugated to the cell-binding agent via an oligosaccharide linker. The glycoconjugates conjugated via the oligosaccharide linkers described herein have improved properties over glycoconjugates of the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Previous application This application claims priority to U.S. Provisional Application No. 63 / 092640, filed on 16 October 2020. The priority application is incorporated herein by reference in whole and for all purposes as if it were fully provided for in this Agreement.

[0002] Field of Invention This invention relates to a complex carbohydrate having a cell-binding agent such as an antibody that binds to a payload such as a drug. The drug is bound to the cell-binding agent via an oligosaccharide linker. [Background technology]

[0003] Antibody therapy is established for targeted treatment of subjects with cancer, immunological and angiogenic disorders (Non-Patent Literature 1). The use of antibody-drug conjugates (ADCs), or immune conjugates, for local delivery of cytotoxic or cell proliferation inhibitors, i.e., drugs that kill or inhibit tumor cells in the treatment of cancer, targets the delivery of the drug portion to the tumor and its intracellular accumulation there. However, systemic administration of these unconjugated drugs can result in unacceptable levels of toxicity to normal cells. (Non-Patent Literature 2-10) This field has advanced with the emergence of a new class of potent toxins such as taxanes, calichemycin, mytansin, duocalmycin, and auristatin. The low toxicity of these substances, ranging from nanomolar to picomolar, has offered a significant advantage over previous generations of toxins. Another technological advancement involves the use of optimized linkers that are hydrolyzable in the cytoplasm, resistant to or sensitive to proteases, or resistant to the multidrug efflux pump associated with highly cytotoxic drugs.

[0004] A common mode for preparing ADCs is the conjugation of the payload (e.g., a drug linker molecule) to the side chain of the antibody amino acid lysine or cysteine. The kinetics of lysine addition mean that conjugation at this residue preferentially occurs on lysine side chains with high steric accessibility and low pKa, making it difficult to control the site specificity of the reaction. Under normal conditions, native antibodies typically do not have free cysteine ​​sulfhydryl groups, so conjugation to cysteine ​​provides greater site specificity. This allows for methods to introduce free sulfhydryl groups into antibody molecules, for example, by selectively reducing existing cysteine ​​or introducing additional cysteine ​​through protein engineering. In either case, the payload can be effectively conjugated to the free sulfhydryl group using electrophilic alkylation based on maleimide addition, for example. This method allows for the efficient and site-selective generation of conjugates. However, given the advantages of conjugates with high product homogeneity and high resistance to off-target release of the payload, research continues to identify conjugation methods that are even better than sulfhydryl alkylation.

[0005] One alternative conjugation technique utilizes azide chemistry (also known as the azide group, or N3 group). In particular, azide groups can selectively cycloadd to terminal alkynes (copper catalyst) or cyclic alkynes (copper-free, with the reaction accelerated by ring strain). The triazoles produced by the reaction with alkynes are particularly resistant to hydrolysis and other degradation pathways. This reaction has been shown to be useful in the production of ADCs (see, for example, Patent Document 1 and Non-Patent Document 11). The potential use in ADC production has also been discussed for ketones and either hydroxylamines or hydrazines (see Patent Document 1). Many strategies have been discussed for introducing the above functional groups into conjugated precursors. One strategy that has been demonstrated to produce safe and effective ADCs involves conjugating a payload of a glycosylated cell-binding agent, such as an antibody (see, for example, Patent Document 2), to the glycan portion. Glycan-mediated conjugation is a potentially versatile strategy for ADC production. For example, all IgG antibodies expressed in mammalian or yeast cell cultures have an N-linked glycan moiety on the Fc portion of each heavy chain. However, this methodology has many challenges. For instance, glycans typically exist as a complex mixture of isoforms, which can contain different levels of galactosylation (G0, G1, G2) and fucosylation (G0F, G1F, G2F), potentially resulting in undesirable heterogeneity in conjugated stoichiometry. Therefore, existing methods often employ one or more "glycan remodeling" steps using enzymes to trim and / or further trim the carbohydrate moiety in order to homogenize the glycan structure as much as possible before conjugation with the payload (Patent Documents 1 and 3, Non-Patent Document 11). However, the vast diversity of available sugar moieties, bindings, branching, chain lengths, and modifying enzymes means that there is a vast genus of possible final structures of the glycan moiety. The final size and structure of glycans influence many important properties of the final complex carbohydrate (e.g., drug-antibody ratio, conjugated hydrophilicity, conjugated hydrodynamics, etc.), many of which cannot be reliably predicted in advance. Therefore, research into favorable glycan configurations is ongoing. Once a glycoprotein is remodeled, several strategies can be considered for its conjugation into the payload. For example, many methods have been reported in which a homogenized glycoprotein is condensed once or multiple times with sugars functionalized with azides or alkynes to produce an activated glycoprotein intermediate, which is then conjugated into the payload using the chemical reactions described above (for details, see, for example, the discussions in Patent Document 1 and Non-Patent Document 11 and the references cited therein). The above method has demonstrated that complex carbohydrates with anticancer effects can be obtained in vivo (see, for example, Patent Document 2). Nevertheless, research is underway to further improve the properties of such complex carbohydrates across a range of cell-binding agents and payloads. [Prior art documents] [Patent Documents]

[0006]

Patent Document 1

Patent document 2

Patent document 3

Non-licensed literature

[0007] [Non-licensed document 1] Carter,P.(2006)Nature Reviews Immunology 6:343-357 [Non-licensed document 2] Xie et al(2006)Expert Opin.Biol.Ther.6(3):281-291 [Non-licensed document 3] Kovtun et al(2006)Cancer Res.66(6):3214-3121

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed literature 9

Non-licensed literature 10

[0008] The inventors investigated the properties of a series of oligosaccharide structures with the aim of identifying an oligosaccharide structure that (1) enables advantageous properties of complex carbohydrates and (2) is easily suitable for commercial-scale production. During their research, the inventors discovered that complex carbohydrates with a relatively short trisaccharide moiety—GlcNAc-Gal-Sia—between the cell binder and the payload possessed a series of advantageous properties. For example, compared to other similar complex carbohydrates with larger oligosaccharide linkers, this class of complex carbohydrates was found to have unexpectedly high hydrophilicity and solubility; significantly faster conjugation kinetics; significantly more effective in vivo (despite similar in vitro activity); better control / consistency for achieving a drug-to-antibody ratio ("DAR") = 2; and significantly improved treatment tolerability by subjects. While not wishing to be constrained by theory, the inventors believe these properties arise in part from the presence and position of the negatively charged sial residue. In some payloads, this was found to be associated with improved efficacy of the complex carbohydrates compared to uncharged sugar moieties at the same position.

[0009] The inventors further determined that advantageous GlcNAc-Gal-Sia complex carbohydrates can be produced using readily available enzyme catalysts. In particular, it was unexpectedly discovered that certain galactosyltransferases can efficiently transfer galactose to GlcNAc residues, preferably α-linked to Asn residues of the peptide backbone (optionally possessing α1-6 fucose), even though this reaction does not occur in the natural system in which these enzymes exist. The resulting galactosyl oligosaccharides were readily susceptible to the addition of modified sialic acid by ST6Gal1 sialyltransferase. Subsequently, the modified sialic acid residues can efficiently bind to a wide range of payloads, such as cytotoxic drugs and other therapeutic agents. Details of one or more embodiments are described below. Other features, subjects, and advantages will become apparent from the description and claims. [Brief explanation of the drawing]

[0010] [Figure 1] This reaction exhibits coupling with glycosylation remodeling by Approach 1. GlcNAc = A-acetyl-glucosamine, Man = mannose, Gal = galactose, Fuc = fucose, Sia = sialic acid, WH = warhead molecule. Reaction conditions: (i) UDP-galactose, galactosyltransferase, MOPS buffer (50mM, 20mM nCl2, pH 7.2), 24 hours; (ii) CMP-Neu5N3, ST6Gal1 sialyltransferase, 1% BSA, alkaline phosphatase, cacodylate buffer (50mM, pH 7.6), 24 hours; (iii) WH-DIBO. [Figure 2]This reaction exhibits conjugation with glycosylation remodeling by Approach 2. GlcNAc = A-acetyl-glucosamine, Man = mannose, Gal = galactose, Fuc = fucose, Sia = sialic acid, WH = warhead molecule. Reaction conditions: (i-1) EndoS; (i-2) EndoS / BtFuchH; (ii) UDP-galactose, β4 GalT 1, MOPS buffer (50mM, 20mM nCl2, pH 7.2), 1% BSA, 1.3% alkaline phosphatase; (iii) CMP-Neu5N3, cacodylate buffer (50mM, pH 7.6), 1% BSA, 1.3% alkaline phosphatase; (iv) WH-DIBO, CuSO4, sodium ascorbate. [Figure 3] The HIC profiles for Her-WH-App1 and Her-WH-App2 are shown. [Figure 4] This shows the in vivo performance of Her-WH-App1 and Her-WH-App2 against the benchmark Her2xADC. [Figure 5] The pharmacokinetics (PK) of Her-WH-App1 and Her-WH-App2 in rats are shown. [Modes for carrying out the invention]

[0011] Before the current methods and systems are disclosed and described, it should be understood that the methods and systems are not limited to specific synthesis methods, specific components, or specific compositions. It should also be understood that the terms used herein are for the purpose of describing specific embodiments only and are not intended to limit them. As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context explicitly indicates otherwise. Ranges may be expressed herein as “about” for one particular value and / or “about” for another particular value. When expressing such ranges, alternative embodiments include ¬ from one particular value and / or ¬ to another particular value. Similarly, when expressing values ​​as approximations, the use of the preceding “about” is understood to indicate that a particular value forms an alternative embodiment. Furthermore, it is understood that each endpoint of a range is important both in relation to the other endpoint and independently of the other endpoint. "Depending on the circumstances" or "in some cases" means that the event or situation described thereafter may or may not occur, and the description includes both cases in which the event or situation occurs and cases in which it does not occur. Throughout this specification, the term “including” and its variations mean “including, but not limited to,” and are not intended to exclude, for example, other additives, components, integers, or processes. “Example” means “one example,” and does not represent a preferred or ideal embodiment. “Etc.” is used for illustrative purposes only, not in a restrictive sense.

[0012] As used herein, the term "clickable group" refers to a functional group that can undergo a cyclic addition reaction with another clickable group under mild conditions that do not denature proteins or other biomolecules.

[0013] As used herein, the terms “drug-to-antibody ratio” or “DAR” refer to the number of drugs bound to an individual antibody, more generally the payload, or more generally the cell-binding agent. Those skilled in the art will understand that in certain biobinding techniques, a uniform number of drugs may not be installed on each antibody of a particular sample. For example, a DAR of 1 indicates that one drug is bound to the antibody, a DAR of 2 indicates that two drugs are bound to the antibody, and so on. In such cases, a non-integer DAR may be specified, for example, 1.5, which indicates that, on average, 1.5 drugs are bound to each antibody of a particular sample.

[0014] As used herein, the term "alkyl" refers to branched or unbranched hydrocarbon groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and dodecyl. Alkyl groups may be substituted or unsubstituted. Unless otherwise specified, the term "alkyl" refers to both substituted and unsubstituted alkyl groups. Alkyl groups can be substituted with one or more groups, including but not limited to alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfooxo, or thiol. Alkyl groups that do not contain double or triple carbon-carbon bonds are called saturated alkyl groups, and alkyl groups that have one or more such bonds are called unsaturated alkyl groups. Unsaturated alkyl groups with double bonds may be called alkenyl groups, and unsaturated alkyl groups with triple bonds may be called alkynyl groups. Unless otherwise specified, the term alkyl includes both saturated and unsaturated groups.

[0015] As used herein, the term "cycloalkyl" refers to a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "heterocycloalkyl" refers to the cycloalkyl group defined above, in which at least one carbon atom of the ring is substituted with a heteroatom such as nitrogen, oxygen, sulfur, selenium, or phosphorus. Cycloalkyl groups and heterocycloalkyl groups can be substituted or unsubstituted. Unless otherwise specified, the terms "cycloalkyl" and "heterocycloalkyl" refer to both substituted and unsubstituted cycloalkyl groups and heterocycloalkyl groups. Cycloalkyl groups and heterocycloalkyl groups can be substituted with one or more groups, including but not limited to alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfoxo, or thiol. Cycloalkyl groups that do not contain double or triple carbon-carbon bonds are called saturated cycloalkyl groups, while cycloalkyl groups that have one or more such bonds (and are not yet aromatic) are called unsaturated cycloalkyl groups. Unless otherwise specified, the term cycloalkyl includes both saturated and unsaturated non-aromatic ring systems.

[0016] As used herein, “aryl” refers to an aromatic ring consisting of carbon atoms. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. “Heteroaryl” refers to the aryl group as defined above, in which at least one carbon atom of the ring is substituted with a heteroatom such as nitrogen, oxygen, sulfur, selenium, or phosphorus. Aryl and heteroaryl groups can be substituted or unsubstituted. Unless otherwise specified, the terms “aryl” and “heteroaryl” refer to both substituted and unsubstituted aryl and heteroaryl groups. Aryl and heteroaryl groups can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfoxo, or thiol.

[0017] Examples of heteroaryl and heterocyclyl rings include: benzimidazole, benzofuranil, benzothiofuranil, benzothiophenyl, benzoxazole, benzoxazolinil, benzenethiazole, benztriazole, benztetrazole, benzisoxazole, benzisothiazole, benzimidazole, carbazole, 4aH-carbazole, carbolinil, chromanil, chromenil, sarnolinil, decahydroquinolinil, 2H,6H-1,5,2-dithiadinyl L, dihydroflo[2,3b]tetrahydrofuran, furanil, furazanil, imidazolidinil, imidazolinil, imidazoleil, lH-indazoleil, indolenil, indolinil, indolinil, 3H-indolyl, isatinoyl, isobenzofuranil, isochromanil, isoindazoleil, isoindolinil, isoquinolinil, isothiazolil, isoxazolil, methylenedioxyphenyl, morpholinil, naphthilidinil, octahydroisoquinolinil, oxadiazoleil, 1,2,3-o Xadiazoli, 1,2,4-Oxadiazoli, 1,2,5-Oxadiazoli, 1,3,4-Oxadiazoli, Oxazolidinyl, Oxazolili, Oxindolyl, Pyrimidinyl, Phenanthrolinyl, Phenanthrolinyl, Phenadinyl, Phenothiazinyl, Phenoxathinyl, Phenoxadinyl, Phthalazinyl, Piperadinyl, Piperidinyl, Piperidonyl, 4-Piperidonyl, Piperonyl, Pteridinyl, Prinyl, Pyrazinyl, Pyrazolidinyl, Pyrazolinyl Pyridazinil, pyridoxazole, pyridoimidazole, pyridothiazole, pyridinil, pyridyl, pyrimidinil, pyrrolidinil, pyrrolinil, 2H-pyrrolyl, pyrrrolyl, quinazolinil, quinolinil, 4H-quinolidinil, quinoxalinil, quinuclidinil, tetrahydrofuranil, tetrahydroisoquinolinil, tetrahydroquinolinil, tetrazoleil, 6H-1,2,5-thiadiadinil, 1,2,3-thiadiazoleil, 1,2,4-thiadiazoleil, 1,2,5-thiadiazoleil, 1,3,Examples include 4-thiadiazoliel, thianthrinyl, thiazoliel, thienyl, thienothiazoliel, thienoxazoliel, thienoimidazoliel, thiophenyl, and xanthenyl. The terms "alkoxy," "cycloalkoxy," "heterocycloalkoxy," "cycloalkoxy," "aryloxy," and "heteroaryloxy" have the above meanings for alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups, and furthermore, the group in question is connected via an oxygen atom.

[0018] As used herein, the term "none" refers to the absence of a group and the direct bonding of two adjacent groups to each other, when referring to the possible identity of a chemical moiety. For example, CH 3- In the case of a compound genus with the formula X-CH3, if X is absent, the resulting compound will be CH 3- I don't know the formula CH3.

[0019] The term "nucleotide" refers to a molecule composed of a nucleic acid base, a five-carbon sugar (ribose or 2-deoxyribose), and one, two, or three phosphate groups. If there are no phosphate groups, the nucleic acid base and sugar form a nucleoside. Therefore, nucleotides are also called nucleoside monophosphates, nucleoside diphosphates, or nucleoside triphosphates. Examples of nucleic acid bases include adenine, guanine, cytosine, uracil, and thymine. Examples of nucleotides include uridine diphosphate (UDP), guanosine diphosphate (GDP), thymidine diphosphate (TDP), cytidine diphosphate (CDP), and cytidine monophosphate (CMP).

[0020] Used in this specification

[0021] [ka] As shown above, two atoms connected by symbols may be connected by a single bond or a double bond. The term "C" used in this specification (x) Alkilen (x is a number) is -(CH2)x This refers to an unsubstituted carbon chain spacer having -. The term allylene refers to an aromatic ring spacer, and heterocyclene refers to a heterocyclic spacer. The substitution pattern can be further specified, for example, phenylene, naphthalene, imidazoylene, etc., and the regiochemistry of the spacer can be further specified, for example, ortho-phenylene, o-phenyl, and 1,2-phenylene all represent phenyl ring spacers in which other groups are bonded to adjacent carbons. The bond configuration of heterocyclene spacers can be specified using IUPAC rules for ring numbering. As an example, X-[1,4-phenylene]-Y is given by the following formula:

[0022] [ka] This refers to compounds that possess [a certain characteristic].

[0023] As used herein, the term “substituted” is considered to include all permissible substituents of an organic compound. In a broad view, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. Exemplary substituents are, for example, those listed below. For a given organic compound, there may be one or more permissible substituents, which may be the same or different. For the purposes of this disclosure, a heteroatom such as nitrogen may have hydrogen substituents that satisfy the valence of the heteroatom and / or permissible substituents of the organic compounds described herein. This disclosure is not intended to be limited in any way by the permissible substituents of the organic compounds. Furthermore, the terms “substituted” or “substituted with” implicitly include the condition that such substitution is subject to the permissible valences of the substituted atom and substituent, and that the substitution results in a stable compound, such as one that does not spontaneously undergo transformation by rearrangement, cyclization, elimination, etc. Unless otherwise specified, a substituent referred to as "substituted" means that it can be substituted with one or more alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfoxo, or thiol groups. In specific examples, a group referred to as substituted is substituted with a protic group that can be protonated or deprotonated depending on the pH. Certain compounds according to the present invention may contain one or more chiral centers and can therefore be prepared and isolated as a racemate or a mixture of isomers, such as a diastereomer mixture, or in enantiomerically or diastereomerically pure form. In the structures shown herein, if the stereochemistry of a particular chiral atom is not specified, all stereoisomers are considered and included as compounds of the present invention. If the stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, the stereoisomers are specified and defined in that way. However, describing a compound without specifying the absolute configuration of the chiral center should not be interpreted as requiring that all possible isomers necessarily be present in all embodiments. The specific compounds of the present invention include ionizable functional groups, such as carboxylic acids, sulfonic acids, phosphonic acids, and amines. Those skilled in the art will understand whether or not such groups contain ionizable hydrogen atoms depending on the pH. A description of a particular compound in a certain ionized state (e.g., protonated) does not preclude other states (e.g., deprotonated) that may exist at different pH levels.

[0024] Unless otherwise specified, the term "patient" refers to any mammal, including but not limited to humans.

[0025] A pharmaceutically acceptable salt is one that retains the desirable biological activity of the parent compound and does not have undesirable toxicological effects. Examples of such salts include acid addition salts formed from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid; salts formed from organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, and polygalacturonic acid; salts formed from elemental anions such as chlorides, bromides, and iodides; salts formed from metal hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, such as sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, such as sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates, such as sodium sulfate and potassium sulfate; and salts formed from metal nitrates, such as sodium nitrate and potassium nitrate. Pharmaceutically acceptable and unacceptable salts can be prepared using procedures known in the art by reacting a sufficiently basic compound, such as an amine, with a suitable acid containing a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium, lithium, etc.) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be prepared.

[0026] Components that can be used to carry out the disclosed methods and systems are disclosed herein. These and other components are disclosed herein, and where combinations, subsets, interactions, bases, etc., of these components are disclosed, specific references to each of the various individual and collective combinations and their permutations may not be expressly disclosed, but it is understood that for all methods and systems, each is specifically considered and described herein. This applies to all aspects of this application, including but not limited to the steps of the disclosed methods. Thus, where there are various further steps that can be carried out, it is understood that each of these further steps can be carried out in any particular embodiment or combination of embodiments of the disclosed methods. Disclosed herein are complex carbohydrates having at least one payload conjugated to a cell-binding agent ("CBA"). The average number of payloads per CBA in formulations from complex reactions may be characterized by conventional means such as UV, reverse-phase HPLC, HIC, mass spectrometry, ELISA analysis, and electrophoresis. The quantitative distribution of CBA by p may also be determined. ELISA may determine the average p value in a particular formulation of CBA (Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Sanderson et al (2005) Clin. Cancer Res. 11:843-852). The complex carbohydrate compositions described herein may be homogeneous, meaning that each cell binder is bound to the same number of payloads. In other embodiments, the complex carbohydrate compositions may include a distribution of conjugates, i.e., several cell binders bound to one payload, several cell binders bound to two payloads, several cell binders bound to three payloads, and so on. Unless otherwise specified, a description of cell binders bound to a particular number of payloads does not preclude the presence of other conjugates.

[0027] In one embodiment, the complex carbohydrate described herein is given by the following formula: [payload] x -Sialoside-Gal-GlcNAc] y -CBA (In the formula, CBA stands for cell binder; GlcNAc represents an N-acetylglucosamine residue, which may be glycosylated at the fucose position C-6; Gal represents a galactosyl residue; Sialoside represents a modified sialic acid residue; The payload represents one or more therapeutic agents covalently bound to a modified sialic acid residue; Each may be the same or different, and represents a drug or diagnostic marker; The payload does not contain pyrrolobenzodiazepines; x represents an integer selected from 1-100, 50-100, 25-50, 1-50, 1-25, 1-16, 1-12, 1-8, or 1-4; and Y is an integer selected from 1, 2, 3, 4, 5, 6, 7, or 8. It is a complex carbohydrate that possesses these properties. In certain embodiments, x may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0028] Modified sialic acid residues (or sialosides) are represented by the following general formula:

[0029] [ka] (In the formula, QQ is a hydrogen or conjugated payload; ZZ represents a hydroxyl group or a conjugated payload; YY is a hydroxyl group or a conjugated payload. XX is a hydroxyl group or a conjugated payload; and In this specification, QQ, ZZ, YY, and XX are represented as conjugate payloads (at least one of them is a conjugate payload). In one embodiment, QQ is a conjugated payload, and each of XX, YY, and ZZ is a hydroxyl group. In another embodiment, ZZ is a conjugated payload, QQ is hydrogen, and XX and YY are their respective hydroxyl groups. In yet another embodiment, ZZ and QQ are their respective conjugated payloads, and XX and YY are their respective hydroxyl groups. In such cases, ZZ and QQ may be the same or different. In one embodiment, the average number of payloads per CBA is in the range of 1 to 4. In another embodiment, the range is selected from 1 to 2, 1 to 3, 2 to 4, 3 to 6, or 4 to 8.

[0030] In one aspect of the present invention, the complex carbohydrate has the following formula:

[0031] [ka] (In the formula, CBA is a cell-binding agent, such as a peptide like an antibody, preferably a monoclonal antibody; The DAR scale y is between 0.5 and 6; preferably between 0.8 and 4, more preferably between 0.8 and 2.2, and even more preferably between 0.9 and 2.1. In one embodiment, y is 0.8–1.2, 0.9–1.1, 1.8–2.2, or 1.9–2.1; R fa This is a hydrogen or fucose portion; QQ is hydrogen, or at least one conjugated payload; ZZ is a hydroxyl group or at least one conjugated payload; YY is a hydroxyl group or at least one conjugated payload; XX is a hydroxyl group or at least one conjugated payload; and In this specification, there may be at least one of QQ, ZZ, YY, and XX (or at least one conjugate payload). In certain cases, the complex carbohydrate may include a mixture of the 2,6 and 2,3 linked oligosaccharides described above. In other embodiments, the complex carbohydrate may consist substantially of 2,6 linked oligosaccharides alone or substantially on 2,3 linked oligosaccharides. In some embodiments, the complex carbohydrate may consist of at least 90%, at least 95%, at least 98%, or at least 99% of 2,6 linked oligosaccharides, and in other embodiments, the complex carbohydrate may consist of at least 90%, at least 95%, at least 98%, or at least 99% of 2,3 linked oligosaccharides.

[0032] In a preferred embodiment, the GlcNAc residue can be bound to CBA via a β-N-glycosidic bond.

[0033] [ka] In other embodiments, the GlcNAc residue can be bound to CBA via an α-N-glycosidic bond. R fa If the part is the fucose portion, then the following formula:

[0034]

Chem.

[0035] In certain embodiments, R fa is hydrogen, while in other embodiments, R fa is fucose. In some embodiments, the composition can have glycoconjugates in which at least 90%, at least 95%, at least 98%, or at least 99% of the glycoconjugates have a hydrogen atom at R fa , while in other embodiments, at least 90%, at least 95%, at least 98%, or at least 99% of the glycoconjugates can have a fucose residue at R fa . In certain embodiments, the cell-binding agent is an antibody, and the oligosaccharide is bound to the antibody via the asparagine side chain through a β-N-glycosidic bond.

[0036]

Chem.

[0037] Provided herein are highly homogeneous complex carbohydrates, meaning that each CBA has the same glycan structure glycosylated to the CBA. For example, in the case of antibodies, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 99% of the individual antibody molecules in the composition may have the same glycan structure. In embodiments in which the oligosaccharide is glycosylated to Asn297, the antibodies can be characterized by having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 99% of the antibody having the same glycan as Asn297.

[0038] As used herein, the term "antibody" is used in its broadest sense, specifically covering monoclonal antibodies, polyclone antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, insofar as they exhibit desirable biological activity (Miller et al (2003) Jour, of Immunology 170:4854-4861). Antibodies may be derived from mouse, human, humanized, chimeric, or other species. Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens (Janeway, C. Travers, P., Walport, M., Shlomchik (2001) ImmunoBiology, 5th edition, Garland Publishing, New York). Target antigens generally have multiple binding sites, also called epitopes, and are recognized by CDRs on multiple antibodies. Antibodies that specifically bind to different epitopes each have a different structure. Therefore, one antigen may have multiple corresponding antibodies. Antibodies include molecules containing a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., an antigen-binding site that immunely binds to a target or a portion thereof, including but not limited to cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. Immunoglobulins can be any type / class (e.g., IgG, IgE, IgM, IgD, IgA) or subtype / subclass (IgG1, IgG2, IgG3, IgG4, IgGA1, IgGA2, etc.) of an immunoglobulin molecule. Immunoglobulins can be derived from any species, including humans, mice, and rabbits. An "antibody fragment" is a portion of a full-length antibody, generally containing its antigen-binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2, and scFv fragments; diabodies; linear antibodies; fragments produced by Fab expression libraries; anti-idiotype (anti-Id) antibodies; CDRs (complementarity-determining regions); epitope-binding fragments that bind immunospecifically to cancer cell antigens, viral antigens, or microbial antigens; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0039] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies; that is, the individual antibodies constituting the population are identical except for any naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific, directed towards a single antigenic site. Furthermore, in contrast to polyclone antibody preparations, which contain different antibodies against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they can be synthesized without contamination by other antibodies. The modifier “monoclonal” indicates the property of an antibody obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with this disclosure are produced by the hybridoma method, first described by Kohler et al. (1975) Nature 256:495, or by the recombinant DNA method (reference: U.S. Patent No. 4816567). Monoclonal antibodies can also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature, 352:624-628 or Marks et al. (1991) J. Mol. Biol., 222:581-597 or from transgenic mice possessing a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).

[0040] Monoclonal antibodies as used herein include, in particular, “chimeric” antibodies in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence of an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the rest of the chain is identical or homologous to a corresponding sequence of an antibody derived from another species or belonging to another antibody class or subclass, and fragments of such antibodies, insofar as they exhibit the desired biological activity (U.S. Patent No. 4816567; and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855). Chimeric antibodies include “prima-formed” antibodies containing a variable domain antigen-binding sequence and a human constant region sequence derived from a non-human primate (e.g., Old World Monkey or Ape).

[0041] In this specification, “intact antibody” includes a VL domain and a VH domain, as well as a light chain constant domain (CL) and a heavy chain constant domain, CH1, CH2, and CH3. The constant domain may be a native sequence constant domain (e.g., a human native sequence constant domain) or an amino acid sequence variant thereof. An intact antibody may have one or more “effector functions” which refer to biological activity resulting from the antibody’s Fc region (native sequence Fc region or amino acid sequence variant Fc region). Examples of antibody effector functions include C1q binding; complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and downregulation of cell surface receptors such as B cell receptors and BCRs. Depending on the amino acid sequence of the heavy chain constant domain, intact antibodies can be assigned to different "classes." There are five main classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into "subclasses," such as IgG1, IgG2, IgG3, IgG4, IgA, and IgGA2. IgG isotypes, particularly the IgG 1 subtype, are preferred. The heavy chain constant domains corresponding to different classes of antibodies are denoted α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional arrangements of different classes of immunoglobulins are well known.

[0042] One technique for reducing the in vivo immunogenicity of non-human antibodies or antibody fragments is "humanization." A “humanized antibody” is a polypeptide comprising at least a portion of a modified variable region of a human antibody, wherein a portion of the variable region, preferably substantially smaller than the intact human variable region, is substituted with a corresponding sequence derived from a non-human species, and the modified variable region is bound to at least another portion of another protein, preferably the constant region of the human antibody. The term “humanized antibody” includes human antibodies in which one or more complementarity-determining region ("CDR") amino acid residues and / or one or more framework region ("FW" or "FR") amino acid residues are substituted with amino acid residues derived from rodents or similar sites of other non-human antibodies. The term “humanized antibody” also includes immunoglobulin amino acid sequence variants or fragments thereof comprising an FR having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin.

[0043] The "humanized" form of a non-human (e.g., mouse) antibody is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. Alternatively, a humanized antibody is a human antibody that also contains sequences selected from a non-human (e.g., mouse) antibody instead of human sequences. Humanized antibodies may contain conserved amino acid substitutions or homogeneous or heterogeneous non-natural residues that do not significantly alter their binding and / or biological activity. Such antibodies are chimeric antibodies containing a minimal sequence derived from a non-human immunoglobulin. There are various humanization techniques, including "CDR transplantation," "guided selection," "deimmunization," "resurfacing" (also called "veniating"), "compound antibodies," "human string content optimization," and framework shuffling.

[0044] The antibody may be intact. The antibody may be humanized, deimmunized, or resurfaced. The antibody may be a fully human monoclonal IgG1 antibody, preferably IgG1,κ. The amino acid numbering used herein follows the EU index numbering system described in Kabat et al. (1991, NIH publications 91-3242, National Technical Information Service, Springfield, Virginia, hereinafter "Kabat"). "EU index described in Kabat" refers to the residue numbers of the human IgG1 EU antibody described in Kabat et al. supra. For example, if substituted with IgG2, IgG3, and IgG4 (or IgA1, IgA2, IgD, IgE, IgM, etc.), a person skilled in the art can easily use a sequence alignment program such as NCBI BLAST (registered trademark) (http: / / blast.ncbi.nlm.nih.gov / Blast.cgi) to align the sequence to IgG1 and determine which residue of the desired isoform corresponds to the Kabat position described herein. In one embodiment, the payload is bound to an N-linked glycan that is linked to an asparagine residue at position 297 of IgG1, according to the EU index described in Kabat. In one embodiment, the antibody is Sd(A) x It is an intact antibody having two N-linked glycans with a portion (i.e., y=2). In one embodiment, the antibody is Sd(A) x It has exactly two N-linked glycans that form a portion.

[0045] In some respects, suitable monoclonal antibodies for use with the conjugates and methods disclosed herein include avagovomab, absiximab, abituzumab, abrazekimab, abrilumab, actoximab, adalimumab, adecatumumab, aducanumab, afasebicumab, aferimomab, arakizumab, alemtuzumab, alirocumab, artumomab, amatsuximab, anatumomab / mafenatox, anddecaliximab, anetumab, aniflorumab, anlukinzumab, apolizumab, aplutumab, and arch Tumomab, aslinbakumab, aselizumab, atezolizumab, atidolotoxumab, atinumab, atrolimumab, avelumab, azintoxizumab, bapinuzumab, basiliximab, bavituximab, BCD-100, bectumomab, beberomab, verantamab, belimumab, bemarituzumab, benralizumab, fazenramab, berlimatoxumab, bermekimab, bersanlimab, bertilimumab, besilezomab, bevacizumab, bezlotoxumab, bisilomab, vimagramab, bimekizumab, vilutamimab, vibatuzumab, brezelumab, buri Natumomab, Brontobetumab, Brosuzomab, Vococizumab, Brazicumab, Brentuximab, Briakinumab, Brodalumab, Brolucizumab, Brontotuzumab, Brosumab, Crisvitamab, Kabilalizumab, Camidanlumab, Camrelizumab, Canakinumab, Cantazumab Meltansine, Cantazumab, Caplacizumab, Capromab, Carrumab, Carotuximab, Catumakisomab, CBR96, Sedelizumab, Semipirimab, Cergutuzumab, Sertolizumab, Cetrerimab, Cetuximab, Sibisatamab, Silmutuzumab, Sitatuzumab Bogatox, cictuzumab, crazakizumab, clenoliximab, cribatuzumab, codolituzumab, cofetuzumab, coltuzumab, conutzumab, concizumab, cosflobiximab, CR6261, crenezumab, chryzanlizumab, clotuzumab, kusatuzumab, dasetuzumab, dacrizumab, darotuzumab, dapyrolizumab, daratumumab, dectrecumab, demcizumab, denintuzumab mafodotin, denosumab, depatuxizumab, delrotuzumab, detumomab, desamizumab, dinutuzumab, dilidabumab, domacrosumab,Dorlimomab, dostallimab, dorodizumab, ds-8201, durigotuzumab, dupilumab, durvalumab, dusigituzumab, duvoltizumab, eclomeximab, eculizumab, edovacomab, edrecolomab, efalizumab, efungumab, erderumab, erezanumab, erugemzumab, elotuzumab, elcilimomab, emactuzumab, emapalmab, emibetuzumab, emicizumab, hemlibra, enapotama, enabatuzumab, enfor Zumab, Enlimomab, Enobrituzumab, Enokizumab, Enokituzumab, Ancituximab, Epitumomab, Epratuzumab, Eptinesumab, Erenumab, Erlizumab, Erzumaxomab, Etalacizumab, Etigirimab, Etrolizumab, Evinacumab, Evolocumab, Exvivirumab, Fanolsomab, Faralimomab, Farisimob, Faretuzumab, Facinumab, FBTA05, Felbizumab, Fezakinumab, Fivatuzumab, Ficlatuzumab Figitumumab, filibumab, frambotumab, freticumab, flotetuzumab, fontrizumab, foralumab, folavirumab, fremanezumab, fresolimmab, flubocimab, flunebetumab, fluranmab, futuximab, garcanesumab, galixumab, gancotamab, ganitam, gantenemab, gatipotumab, gabirimomab, gedivumab, gemtuzumab, gebokizumab, gilbetuzumab, gymcirumab, gilentiximab, grembatumab Golimumab, Gomiliximab, Goslanemab, Guselkumab, Ianalumab, Ivarzumab, IBI308, Ibritumomab, Ikulcumab, Idarucizumab, Ifabotuzumab, Igovomab, Iradatuzumab, IMAB362, Imarumab, Imaprelimab, Imsilomab, Imugatuzumab, Incrakumab, Indatuximab / Labtansine, Indosatumab / Vedotin, Innebilizumab, Infliximab, Inorimomab, Inotuzumab, Intetumumab, IOMAB-B, Ipilimumab, Iratumumab, Isatuximab, Ikarimumab, Isilatumab, Itorizumab, Isekizumab, Keriximab, Labetuzumab, Lacunotuzumab, Radilatuzumab, Lamparizumab, Lanadermab, Landoglotumab, Laprituximab, Larcabiximab, Lebrikizumab, Remalesomab, Rendarizumab, Lembervimab, Renzirumab, Rerdelimumab, Leronlimab, Rezofabumab, Retrizumab, Lexatumumab, Rivivirumab, Rifastozumab, Rigerizumab, Rilotomab / Satetraxetan, Phosphate Tozumab, lirirumab, rodelcizumab, lokibetsumab, loncastaximab, rorbotuzumab, rosatuxizumab, lucatumab, rulizumab, lumiriximab, lumuretuzumab, rupaltomab / amadotin, rutikizumab, mapatumumab, margetuximab, mastacimab, masumlimuab, matsuzumab, mebrimumab, mepolizumab, metelimumab, miratozumab, minretumomab, mirikizumab, milbetuximab / sorabutansine, mitumomab, modotuximab, mogamulizumab, monalizab, morolimusumab, mozunetuzumab, motabizumab Moxetumomab, Muromonab-CD3, Nacolomab / Tafenatox, Namilumab, Naptomomab, Naratuximab, Narunatumab, Natalizumab, Nabisikizumab, Navibumab, Naxitamab, Nevacumab, Necitumab, Nemolizumab, NEOD001, Nererimomab, Nezbakumab, Netakimab, Nimotuzumab, Nilsevimab, Nivolumab, Nofetumomab, Oviltoxakimab, Obinutuzumab, Okalatuzumab, Oclerizumab, Odulimomab, Octatumumab, Oralatumab, Oredalizumab, Orodalizumab, Orokizumab, Omari Zumab, ombrutamab, OMS721, onartuzumab, ontoxizumab, ombatirimab, opicinumab, oportuzumab, olegobomab, orticumab, otericuzumab, otilimab, otraltuzumab, oxelumab, ozanezumab, ozoralizumab, pagibaximab, palivizumab, pamrebrumab, panitumumab, pancomab, panobacumab, pasatuzumab, pascorizumab, pasotuxizumab, patecrituzumab, patrizumab, PDR001, pembrolizumab, pemtumomab, perakizumab, pertuzumab, pexelizumab,Pidilizumab, pinatuzumab, pintotumomab, pracumab, prozarizumab, pogalizumab, polatuzumab, ponesumab, polgabiximab, pracinesumab, prezarizumab, priliximab, pritoximab, pritumumab, PRO140, kirizumab, lacosumomab, radrezumab, rafivirumab, larpancizumab, ramucirumab, ranebetuzumab, ranibisumab, labagalimab, ravulizumab, laxibakumab, refanezumab, regavirumab, allerimab, remtolumab, reslizumab, rilotomab, linucumab, risankizumab, li Tuximab, ribabazumab, lobatumumab, lorezumab, romilukimab, romosozumab, lontarulizumab, rosmantozumab, lovalpituzumab tesirin, loberizumab, rozanolixizumab, luprizumab, SA237, sacituzumab, samarizumab, samlotamab, sarilumab, satralizumab, satsumab, secukinumab, sericrelumab, ceribantomab, cetoxaximab, cetoluzumab, sevilumab, SGN-CD19a, SHP647, cibrotuzumab, cifalimumab, siltoximab, simtuzumab, ciprizumab, siltratuzumab, Silkumab, sofituzumab, solanetuzumab, solitomab, soneptizumab, sontuzumab, spartalizumab, stamlumab, thresomab, subtabumab, stimulimab, subizumab, subbratoxumab, tabarumab, takatuzumab, tadocizumab, tarakotsuzumab, talizumab, tamtsubetuzumab, tanezumab, tapritumomab, tarextomab, tabolimab, tefivazumab, terimomab, terisotuzumab, tenatomomab, teneriximab, teprizumab, tepositamab, teprotuzumab, tesidorumab, teturomab, tezeperumab, TGN1412, Tibrizumab, Tibrizumab, Tigatuzumab, Tildorakizumab, Timigutuzumab, Timorumab, Tiragotuzumab, Tislizumab, Tisotuzumab, TNX-650, Tocilizumab, Tomzotuximab, Traluizumab, Tosatoxumab, Tositumomab, Tobetuzumab, Tralokinumab, Trastuzumab, TRBS07, Tregalizumab, Tremerimab, Trevoglumab, Tucotsuzumab, Tubilumab, Yubrituzumab, Urokoplumab, Urelumab, Ultraxazumab, Austekinimab, Oatmilumab, Vataximab, Banalizumab,Examples include banalomab, bundletuzumab, vanitutuzumab, vanucizumab, bapariximab, valisakumab, valirumab, baterizumab, vedolizumab, berutuzumab, vapalimomab, besenkumab, bicilizumab, bovalizumab, borosiximab, bonrelorizumab, voplaterimab, borsetuzumab mafodotin, botumab, bunakisumab, zentozumab, XMAB-5574, zalzumab, zanorumab, zatuximab, xenoctatuzumab, dilarumab, zolbetuximab, and zolimoma.

[0046] The conjugation chemistry described herein allows the glycosylated cell-binding agents described herein to be conjugated to a wide range of payloads. For example, in some embodiments, the payload may be or include therapeutic agents (therapeutic proteins, lipids, nucleic acids, etc.), markers or imaging agents (radionuclides, phosphors, dyes, etc.), drugs, antibiotics, vaccines, immunosuppressants, adjuvants, or protective agents. A preferred class of payload consists of a drug (also referred to herein as the "drug portion"), and by attaching the drug to a cell-binding agent, the drug can be delivered to target cells with high precision. A drug molecule is a drug or a prodrug. In some embodiments, the drug is selected from groups consisting of pharmaceutically active compounds, particularly low to medium molecular weight compounds (e.g., about 200 to about 2500 Da, preferably about 300 to about 1750 Da). In some embodiments, the drug may be one or more cytotoxic agents, immunomodulators, antiviral agents, antibacterial agents, peptides, and oligonucleotides. Representative drugs include colchicine, vinca alkaloids, anthracyclines, camptothecin, doxorubicin, daunorubicin, taxanes, pyridinobenzodiazepines (PDDs), calicheamicin and other enediyne compounds, tubulisin, exatecan, irinotecan, inhibitory peptides, amanitin, debuganin, duocalmycin, meitansine or auristatin, vinca alkaloids, anthracyclines, taxanes, amanitin, and especially vinca alkaloids, anthracyclines, camptothecin, taxanes, tubulisin, amanitin, meitansine and auristatin. For the avoidance of doubt, this drug shall not be a pyrrolobenzodiazepine (PBD), that is, a compound comprising the following substructure:

[0047] [Chemical Formula] shall not be a compound comprising the same.

[0048] As used herein, any atom may be further substituted with any functional group. In a preferred embodiment, the drug moiety is conjugated to the glycosylated cell-binding agent described herein via a linker moiety (a so-called "drug-linker" payload), generating a conjugate in which one or more drugs are bound to the same sialoside. [[Drug-linker] z -Sialoside-Gal-GlcNAc] z -CBA, As used herein, one or more of the positions QQ, XX, YY, ZZ on the sialoside defined above are linker payloads, and z is independently selected from 1, 2, 3, 4, 5, 6, 7, or 8 each. In certain embodiments, a plurality of drugs may be conjugated to the same linker bound to the sialoside, which has the formula below. [Drug] z -Linker-Sialoside-Gal-GlcNAc] z -CBA. In other embodiments, a plurality of drugs may be bound to the same linker, and a plurality of linkers may be bound to the sialoside with the formula below. [[Drug] z -Linker] z -Sialoside-Gal-GlcNAc] z -CBA.

[0049] In certain embodiments, the linker may comprise a ring system resulting from a cycloaddition reaction between a 1,3-dipole and a strained cycloalkyne or a strained trans cycloalkene. Therefore, in some exemplary embodiments, the payload is coupled to the sialoside at the QQ position, as follows:

[0050] [ka] In this specification, L is a linker. In some exemplary embodiments, the payload is coupled to the sialoside at the ZZ position, and thus as follows:

[0051] [ka] In yet another embodiment, the payload (e.g., drug) is bound to the sialoside at the QQ and ZZ positions. The payload and linker may be the same or different.

[0052] Various cytotoxic compounds function as payloads. In some embodiments, the payload includes DNA damaging agents, tubulin polymerization inhibitors (also known as microtubule inhibitors or microtubule destabilizers), topoisomerase inhibitors, RNA splicing inhibitors, or RNA polymerase inhibitors. The term "DNA damaging agent" as used herein does not include the pyrrolobenzodiazepine compounds defined above. In some embodiments, the conjugate may contain at least two different drugs extracted from the above classes. For example, the conjugate may contain multiple DNA damaging agents or multiple microtubule inhibitors. In some cases, the conjugate may contain at least one DNA damaging agent and at least one microtubule inhibitor. In other embodiments, the conjugate may contain at least one DNA damaging agent and at least one topoisomerase inhibitor. In further embodiments, the conjugate may contain at least one microtubule inhibitor and at least one topoisomerase inhibitor. In yet another embodiment, the conjugate may contain at least one microtubule inhibitor, at least one DNA damaging agent, and at least one topoisomerase inhibitor. Suitable DNA damaging agents include enediyne compounds, doxorubicin compounds, and duocalmycin compounds. Suitable microtubule inhibitors include drastatin compounds, taxanes, vinca alkaloids, maytansine compounds, tubulicin compounds, eribulin compounds, and critophycin compounds. Suitable topoisomerase inhibitors include camptothecin compounds and lamelarin compounds. Other types of payloads, such as immunostimulants, may also be coupled to the drug.

[0053] In one embodiment, the payload may include engine-based antitumor antibiotics, such as calicheamicins, shisimycins, unciaramycins, neocardinostatins, esperamycins, dynemycins, and golfomycins. In some examples, the payload is expressed as follows:

[0054] [ka] (In the formula, R ch 1 or R ch 2 One of them is a linker bonded to the terminal sialoside. If it is not a linker, R ch 1 H, -SS-CH 3、 C(O)CH 3、 Alternatively, it may be a sufficiently unstable group that can be cleaved to yield a free thiol. If it is not a linker, R ch 2 H, C 1~4 Alkyl, or C(O)C 1~4 This may include calicheamycin compounds having an alkyl group.

[0055] In some cases, the payload may contain the following formula:

[0056] [ka] (In the formula, R sh 1、 R sh 2、 or R sh 3 One of these is a linker conjugated to the terminal sialoside. If it is not a linker, R sh 1 H, -SS-CH 3、 C(O)CH 3、 Alternatively, it may be a sufficiently unstable group that can be cleaved to yield a free thiol. If it is not a linker, R sh 2 H, C 1~4 Alkyl, or C(O)C 1~4 It can be alkyl. If it is not a linker, R sh 3 (This could be H) This may include a shishijimicin compound that possesses the following properties:

[0057] In some cases, the payload may contain the following formula:

[0058] [ka] (In the formula, R un1、 R un2、 R un3、 R un4 , R u 5 One of them is a linker conjugated to the terminal sialoside, and the rest are H. This can include unciaramycin compounds that have [specific characteristic].

[0059] In some examples, the payload is expressed as follows:

[0060] [ka] (In the formula, R un1、 R un2、 R un3、 R un4 , R u 5 One of them is a linker conjugated to the terminal sialoside, and the rest are independently H or C 1~4 (It is alkyl.) It may contain neocardinostatin compounds that have the properties of neocardinostatin.

[0061] In some examples, the payload is expressed as follows:

[0062] [ka] (In the formula, R es 1、 R es 2、 R es 3、 R es 4 , R es 4 , R es 5 , R es 6 , R es 7 , R es 8 Either of these is a linker bonded to the terminal sialoside. If it is not a linker, R es 1 H, -SS-CH 3、 C 1~4 Alkyl, C(O)CH 3、 Alternatively, it may be a sufficiently unstable group that can be cleaved to yield a free thiol. If it is not a linker, R es 2、 R es 3 , R es 4、 R es 4 , R es 5 , R es 6 , R es 7 and R es 8 H and C are independent of each other. 1~4 Alkyl, or C(O)C 1~4 It may contain espalamycin compounds that are alkyl.

[0063] In some cases, the payload is expressed as follows:

[0064] [ka] (In the formula, R dy 1、 R dy 2、 R dy 3、 R dy 4 , R dy 4 , R dy 5 , R dy 6 One of them is a linker bonded to the terminal sialoside, and the rest are independently H or C 1~4 (It is alkyl.) It may be a dynemycin compound having [a specific characteristic].

[0065] In other examples, the payload is expressed as follows:

[0066]

Chemical formula

[0067] In some embodiments, the payload may be a dolastatin compound, for example, dolastatin 10 or a dolastatin 15 analog. In certain embodiments, the dolastatin compound has, for example, the following formula:

[0068]

Chemical formula

[0069] In other embodiments, the payload has the following formula:

[0070]

Chemical formula

[0071] In other cases, the payload may contain an ansamitosine derivative, for example, the following formula:

[0072] [ka] (In the formula, R me (This is a linker bonded to the terminal sialoside.) This may include meltansine compounds having [specific characteristic].

[0073] In further embodiments, the payload may contain a vinca alkaloid, for example, the following formula:

[0074] [ka] (In the formula, R v is CH3 or C(O)H; R v 1 It is a linker bonded to an OH, OAc, or terminal sialoside; R v 2 OH, OCH 3、 or a linker bonded to a terminal sialoside; and R v 3 (It either does not exist, or it is a linker bonded to the terminal sialoside.) This may include vincristine / vinblastine compounds having [specific characteristic].

[0075] In other embodiments, the payload is given by the following formula:

[0076] [ka] (In the formula, R er This may include eribulin compounds having a linker bonded to the terminal sialoside.

[0077] In other embodiments, the payload is expressed as follows:

[0078] [ka] (In the formula, R c 1 is a linker to H or terminal sialoside; R c 2 It is a linker to H, CH2CH3, or terminal sialoside; R c 3 is H, OH, CH3; or a linker to a terminal sialoside; R c 4 is H or F; and R c 5 (This is a linker to NH2 or terminal sialoside.) It may contain a camptothecin compound having the following properties:

[0079] Other compounds that can be included in the payload are given by the following formula:

[0080] [ka] (In the formula, R du 1 is a linker to H or terminal sialoside; and R du 2 is C 1~8 Alkyl, OC 1~8 It is a duocalmycin compound having an alkylphenyl, 4-hydroxyphenyl, or linker to a terminal sialoside.

[0081] In one embodiment, the payload is given by the following formula:

[0082] [ka] (In the formula, R tx1 is a linker to -C(O)Ph, --C(O)OtBu, or terminal sialoside; R tx2 H is a linker to the terminal sialoside; R tx3 is -C(O)CH 3、 It is an OMe or a linker to the terminal sialoside; R t 4 is phenyl or -CH=C(CH 3)2It contains a taxane compound that has the following properties:

[0083] In one embodiment, the payload is given by the formula:

[0084] [ka] (In the formula, X cr is either O or NH; R CR2 is H or CH3; and R cr 3 (This is a linker to the terminal sialoside.) It contains cryptophysin compounds having the following properties.

[0085] In some cases, other tubulin inhibitors such as hemiastalin (HTI-286), colchicine, discodermorid, tacaronolide A, tacaronolide B, and tacaronolide AF may be included in the payload. Takaronolide AJ, Takaronolide AI-Epoxide, Laurimalide, Epothiron A, or Epothiron B. The linker connects the payload to the terminal sialoside, which in one embodiment can be represented as follows:

[0086] [ka] (In the formula, the payload is as defined above, Het represents a heterocyclic system, L1 is selected from Het to payload with or without a sublinker, L 2 x1 is an integer selected from Het to sialoside or from a sublinker, where x1 is an integer selected from 1, 2, 3, 4, 5, 6, 7, or 8; x2 is an integer selected from 1, 2, 3, 4, 5, 6, 7, or 8; x3 is an integer selected from 1, 2, 3, 4, 5, 6, 7, or 8. (In embodiments where one linker has multiple payloads (i.e., at least one of x1, x2, or x3 > 1), the payloads may be the same or different.) Embodiments characterized by multiple linker-payload portions coupled to the same sialoside (i.e., at least two of QQ, XX, YY, ZZ are conjugated payloads), payload, Het, L 1 , L 2 x1, x2, and x3 may be identical or different. Typical heterogeneous systems include fused polycyclic heterogeneous systems.

[0087] [ka] (In this specification, H 1 represents a heterocycle, and A represents a carbocyclic or heterocycle, preferably a ring having eight atoms in its ring skeleton. Typical eight-atom rings include cyclooctane, cyclooctene, aza-cyclooctane, aza-cyclooctene, 2-azacyclooctanone, and their unsaturated derivatives. In some embodiments, an eight-atom ring can be condensed into one or more aromatic rings.

[0088] H 1 The heterocycle represented by can be produced from a cyclic addition reaction between (a) a 1,3-dipole or 1,2,4,5-tetrazine and (b) a strained alkyne or strained alkene. Preferred strained alkynes include cyclooctyne, and preferred strained alkenes include trans-cyclooctene. Heterocycles include, but are not limited to, triazoles, 1,2-pyridazines, oxazoles, isoxazoles, oxadiazoles, and saturated and partially unsaturated analogs of such rings.

[0089] In one embodiment, for example (x2 and x3=1), the complex algebra is given by the following equation:

[0090] [ka]

[0091] [ka] (In the formula, x is as defined above, R H 1 H, C 1~4 Alkyl, aryl, C 1~4 Selected from Alkali, L 1 or L 2 They may form a ring together; R H 2 H, C 1~4 Alkyl, aryl, C 1~4 Selected from Alkali,

[0092] [ka] (This represents a single bond or a double bond.) It is possible to have it.

[0093] In a specific embodiment, ring A is defined by the following formula:

[0094] [ka] (In the formula, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ Each of these is independent: none, H, F, Cl, Br, I, C 1~4 Alkyl, C 1~4 Selected from alkoxy and aryl; and, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ One of the following is L 1 or L 2 It is fine to be; RA 1 RA 1’ RA 2 RA 2’ RA 3 RA3’ RA 4 , and RA 4’ Two or more of these can together form a ring; for example, R A1 and R A2 , and R A3 and R A4 Both can form aromatic rings, but R A1’ , R A2’ , R A3’ , and R A4’ None of them are; RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ Any of the L 1 or L 2 In this case, W may be CH2CH2; RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ All of them are L 1 and L 2 Otherwise, W is given by the following formula:

[0095] [ka] (In the formula, L 1 / 2 is L 1 or L 2 (Represents one of the following) It may be a group having; in this specification, W, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ L 1 If it includes W, RA 1 RA 1’ RA 2 RA 2’ RA3 RA 3’ RA 4 , and RA 4’ All of them are L 2 Does not include; and W, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ L 2 If it includes W, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ All of them are L 1 It can have (not including)

[0096] In one embodiment, the A ring is given by the following formula:

[0097] [ka] It is possible to have it.

[0098] Although not shown above, L 1 When L is bonded to an 8-atom ring, 2 It is understood that these are coupled to a complex algebra, and vice versa. In one embodiment, L 2 It is optional, or the following formula: -L2 1 -L2 2 -L2 3 -L2 4 -L2 5 -L2 6 - (In the formula, L2 1 It is bonded to a heterocyclic system, and there is no C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 21OC(=O), OC(=O)NR 21 , NR 21 C (=O), NR 21 C(=O)O, NR 21 C(=O)O, NR 21 C(=O)NR 21 Selected from OC(=O)O, as specified herein, R 21 H or C 1~4 It is alkyl; L2 2 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 22 OC(=O), OC(=O)NR 22 , NR 22 C (=O), NR 22 C (=O), NR 22 C(=O)O, NR 22 C(=O)NR 22 Selected from OC(=O)O, as specified herein, R 22 H or C 1~4 It is alkyl; L2 3 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, S, poly(ethylene), poly(acetal); poly(glycerol), O, NR 23 OC(=O), OC(=O)NR 23 , NR 23 C (=O), NR 23 C (=O), NR 23 C(=O)O, NR 23 C(=O)NR 23 Selected from OC(=O)O, as specified herein, R 23 H or C 1~4 It is alkyl; L2 4 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 24 OC(=O), OC(=O)NR 24 , NR 24C (=O), NR 24 C (=O), NR 24 C(=O)O, NR 24 C(=O)NR 24 Selected from OC(=O)O, as specified herein, R 24 H or C 1~4 It is alkyl; L2 5 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 25 OC(=O), OC(=O)NR 25 , NR 25 C (=O), NR 25 C (=O), NR 25 C(=O)O, NR 25 C(=O)NR 25 Selected from OC(=O)O, as specified herein, R 25 H or C 1~4 It is alkyl; L2 6 It is bound to the sialoside, and none, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 26 OC(=O), OC(=O)NR 26 , NR 26 C (=O), NR 26 C (=O), NR 26 C(=O)O, NR 26 C(=O)NR 26 Selected from OC(=O)O, as specified herein, R 26 H or C 1~4 It may also be a group that is alkyl. In a particular embodiment, L2 1 , L2 2 , L2 3 , L2 4 , L2 5 , L2 6 Any two or more of these can form a ring together. A person skilled in the art will know L2 1 , L2 2, L2 3 , L2 4 , L2 5、 and L2 6 If you select "none" for each of these, you will understand that an embodiment in which L2 is "none" will be generated. In a particular embodiment, L2 6 In one embodiment, it is NHC(O)NH, but in another embodiment, L2 6 These include, for example, triazoles, 1,2-pyridazines, oxazoles, isoxazoles, oxadiazoles, and heterocyclyls or heteroaryls, which are saturated and partially unsaturated analogs thereof. In a particular embodiment, L2 1 This is allylene, for example, 1,4-phenylene. In one embodiment, L2 1 is none, OC(O)NH, C 1~8 Alkylene, preferably C 1~3 Alkylene or allylene, for example, 1,4-phenylene; L2 2 is none or C 1~8 Alkylene, preferably C 1~3 It is alkylene; L2 3 is none, C(=O)NH, NHC(=O), NHC(=O)O, or OC(=O)NH; L2 4 is none or poly(ethylene); L2 5 is none or C 1~8 Alkylene, preferably C 1~3 It is alkylene; L2 6 This is none, or heterocyclyl or heteroaryl compounds, such as triazole, 1,2-pyridazine, oxazole, isoxazole, oxadiazole, and their saturated and partially unsaturated analogs. In a particular embodiment, L2 1 OC(O)NH and L2 2 , L2 3 , L2 4 , L2 5 , and L2 6 None of them are included.

[0099] For example, x, L2 1 , L2 2, L2 3 , L2 4 , L2 5 , and L2 6 When a specific selection is made for this, the following substructure is formed:

[0100] [ka]

[0101] [ka]

[0102] [ka]

[0103] [ka] (In the formula, L1, payload, R) h2 A, QQ, ZZ, YY, and XX are defined as above. As described above, multiple payloads from QQ, ZZ, YY, and XX can be made into a conjugate payload, and embodiments are generated that have the same payload and can have the same or different linkers.

[0104] In one embodiment, L1 can be omitted, as shown in the following equation: -L1 1 -L1 2 -L1 3 -L1 4 -L1 5 -L1 6 - (In the formula, L1 1 It is bonded to a heterocyclic system, and there is no C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 11 OC(=O), OC(=O)NR 11 , NR 11 C (=O), NR11 C(=O)O, NR 11 C(=O)O, NR 11 C(=O)NR 11 Selected from OC(=O)O, as specified herein, R 11 H or C 1~4 It is alkyl; L1 2 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 12 OC(=O), OC(=O)NR 12 , NR 12 C (=O), NR 12 C (=O), NR 12 C(=O)O, NR 12 C(=O)NR 12 Selected from OC(=O)O, as specified herein, R 12 H or C 1~4 It is alkyl; L1 3 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, S, poly(ethylene), poly(acetal); poly(glycerol), O, NR 13 OC(=O), OC(=O)NR 13 , NR 13 C (=O), NR 13 C (=O), NR 13 C(=O)O, NR 13 C(=O)NR 13 Selected from OC(=O)O, as specified herein, R 13 H or C 1~4 It is alkyl; L1 4 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 14 OC(=O), OC(=O)NR 14 , NR 14 C (=O), NR 14 C (=O), NR 14 C(=O)O, NR 14C(=O)NR 14 Selected from OC(=O)O, as specified herein, R 14 H or C 1~4 It is alkyl; L1 5 No, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 15 OC(=O), OC(=O)NR 15 , NR 15 C (=O), NR 15 C (=O), NR 15 C(=O)O, NR 15 C(=O)NR 15 Selected from OC(=O)O, as specified herein, R 15 H or C 1~4 It is alkyl; L1 6 It is bound to the payload, and none, C 1~8 Alkylene, allylene, heteroaryl, heterocyclyl, poly(ethylene), poly(acetal), poly(glycerol), S, O, NR 16 OC(=O), OC(=O)NR 16 , NR 16 C (=O), NR 16 C (=O), NR 16 C(=O)O, NR 16 C(=O)NR 16 Selected from OC(=O)O, as specified herein, R 16 H or C 1~4 (It is alkyl.) It can also be used as a base that has [something]. In a particular embodiment, L1 1 , L1 2 , L1 3 , L1 4 , L1 5 , and L1 6 Any two or more of these can form a ring together. L1 3 This is a branched C 1~8 It may be an alkylene, allylene, heteroaryl, or heterocyclyl group. For example, L13 The following formula:

[0105] [ka] (In the formula, y1 is any permissible substitution number in valence.) It may be a phenyl group having . In the above exemplary formula, x1 may be 1, 2, 3, 4, or 5. A skilled person may use other possible L1 3 It is recognized that this creates the possibility of x1 having different bases. In other examples, L1 3 This is a branched alkylene, for example, in the following formula:

[0106] [ka] (In the formula,) It may be a methylene group having the following formula:

[0107] [ka] mosquito It is methine.

[0108] In one embodiment, L1 3 This is a polymer group, for example, the following formula:

[0109] [ka] It may contain poly(glycerol) having the following formula:

[0110] [ka] (In the formula, y is between 1 and 1,000; R 456 is hydrogen or formula (456):

[0111] [ka] And R456 A portion of a polyacetal having the formula (where the number of times it is part of formula 456 is less than 30) is selected.

[0112] A cleavable L1 group contains at least one functional group that is subject to bond cleavage under environmental conditions. Cleavable groups include acid-sensitive groups, redox-sensitive groups, and enzyme-cleavable groups, such as protease-cleavable groups. Typical acid-sensitive groups include Schiff bases / imines, hydrazones, boronic acid esters, and acetals. Typical redox-sensitive groups include thioacetals, oxalic acid esters, disulfides, peptides, and diselenide groups. Examples of enzyme-cleavable groups include the peptide fragments Val-Lys, Val-Ala, Val-Arg, Phe-Lys, and Val-Cit. In some cases, L1 may include a self-fixing spacer. A self-fixing spacer is a chemical moiety bonded to a selectively cleavable group, and activation of the cleavable group results in a reaction cascade that ultimately releases the payload from the spacer. Typical self-fixing spacers include p-aminobenzyl alcohol, p-hydroxybenzyl alcohol, 2-aminoimidazole-5-methanol moiety, ortho- or para-aminobenzyl acetal, aminobutyric acid amide, 1,2-diaminoethylene, and 1,3-diaminopropylene. In one embodiment, L1 is a self-fixing spacer, a severable base, and any further linker, for example, of the following formula:

[0113] [ka] (In the formula, R SIP This is one or more self-adjusting spacers; RC L It is a cleavable group; R L1 If present, it is a further linker; x1.5 is an integer selected from 1, 2, 3, 4, 5, 6, 7, and 8; and, x1.6 is an integer selected from 1, 2, 3, 4, 5, 6, 7, and 8. It may include a conjugate having the following properties.

[0114] If the payload contains a functionalizable amine or alcohol group, the payload may be bonded to L1 or RSIP via, for example, a carbamate, carbonate, phosphonate, or sulfonate group: i.e.,

[0115] [ka] In the embodiments shown below, x1.5, x1.6, and x3 are all selected to be 1. Furthermore, embodiments in which these variables are greater than 1 are also conceivable within the scope of the present invention.

[0116] [ka] X is an oxygen or nitrogen atom in the payload, and X z is O, NH, or NC 1~4 It is alkyl. The benzyl self-fixed spacer shown above may be further substituted one or more times with electron-withdrawing groups such as nitro, fluoro, or trifluoromethyl. ea 1 and R ea 2 H, C 1~4 Alkyl, or (CH2CH2O) n CH2CH2OH (where n is 0, 1, 2, or 3) can be independently selected. For example, the auristatin family of payloads has a secondary amine functional group (i.e., R au 1 forms a linker, R au 2 It can be conjugated via hydrogen:

[0117] [ka] R CL In some cases, it may be a peptidyl residue.

[0118] [ka] (In the formula, z is 1 or 0, z1 is 1 or 0, R CC H, peptidyl, C 1~6 Alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, R aa 1、 R aa 2、 and R aa 3 Phenyl, COOH, NH 2、 COHNH 2、 In NHC(O)NH2, H and C may be substituted in some cases. 1~6 (Selected independently of alkyl).

[0119] In a particular embodiment, z1 is 0, and R aa 1 It is isopropyl, and R aa 2 (-CH 2)4 NH 2、 (-CH 2)3 NHC(O)NH 2、 (-CH 2)3 NHC(NH)NH 2、 Or it is CH3. In other cases, z1 is 0 and R aa 1 It is benzyl, and R aa 2 (-CH 2)4 It is NH2. In yet another embodiment, z1 is 1, R aa 1 isopropyl, R aa 2 (-CH 2)3 NHC(O)NH 2、 R aa 3 (-CH 2) It is COOH.

[0120] The formula for a peptidyl residue is as follows:

[0121] [ka] or

[0122] [ka] (In the formula, R cc ,z,z1,R aa 1 ,Raa 2 ,R aa 3 ,R SIP (As defined above) it can have. In some examples, R SIP It can be a 4-aminobenzyl alcohol with the following formula: The case where z1 is 0 is exemplified below.

[0123] [ka] (In the formula, if z1 is 1, R SIP (This may be 4-aminobenzyl alcohol).

[0124] In some cases, R CL The following formula:

[0125] [ka] It is a peptide group that has [a specific characteristic].

[0126] In other embodiments, R CL This can be a gluconic acid residue, for example:

[0127] [ka] In other embodiments, the cleavable group may be a disulfide.

[0128] [ka] (In the formula, R ds 1 and R ds 2 H or C 1~4 (It is alkyl.) In some cases, R ds 1 and R ds 2 Both are hydrogen, or R ds 1 and R ds 2 Both are methyl. In other examples, R ds 1 is hydrogen, R ds 2 is C 1~4 It is alkyl. If the payload contains ketones or aldehydes, cleavable groups may include hydrazones.

[0129] [ka] Hydrolysis of hydrazones is thought to release the payload at the original carbonyl group. For example, a doxorubicin payload bound to a hydrazone can be used.

[0130] [ka] Payloads containing carboxylic acid functional groups can also be bound with hydrazones.

[0131] [ka] (In the formula, R hy is H or C 1~4 (Representing alkyl, preferably methyl).

[0132] For example, vincristine-type payloads can be coupled with hydrazones.

[0133] [ka] R L1 The following formula:

[0134] [ka] (In the formula, R L1 A No, C 1~10 Alkylene, aryl, -(CH2CH2O) a - Select from the options. R L1 B None, NHC(O)O, NHC(O)NH, OC(O)NH, O, NR zz Selected from (as specified herein, R zz is H or C1~4 Alkyl, NHC(O), C(O)NH, C 1~10 Alkylene, aryl, -(CH2CH2O) a -is / are R L1C No, C 1~10 Alkylene, aryl, -(CH2CH2O) a - Selected from; R L1 D None, NHC(O)O, NHC(O)NH, OC(O)NH, O, NR zz (In this specification, R zz is H or C 1~4 Alkyl, NHC(O), C(O)NH, C 1~10 Alkylene, aryl, -(CH2CH2O) a - Selected from; R L1 E NHC(O)O, NHC(O)NH, OC(O)NH, O, NR zz (In this specification, R zz is H or C 1~4 Alkyl, NHC(O), C(O)NH, C 1~10 Selected from alkylenes; aryl, -(CH2CH2O) a -; In this specification, a is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In other embodiments, a may be any of 1-50, 10-100, 5-10, 5-25, 25-50, or 50-100. a1 is selected from 1, 2, 3, or 4; and a2 can be represented as (selected from 1, 2, 3, 4, 5, 6, 7, 8).

[0135] In some cases, R L1 The following formula:

[0136] [ka]

[0137] [ka] (In the formula, R L1 A , R L1 B , R L1C , R L1 D (and a1 is as defined above) It is possible to have it.

[0138] In some cases, R L1 The following formula:

[0139] [ka] (In the formula, R L1 A (and a1 are as defined above) It is possible to have it.

[0140] Manufacturing method The complex carbohydrates disclosed herein are given by the following formula:

[0141] [ka] or

[0142] [ka] (In the formula, R fa , y, and CBA are as defined above; Q is H or L 2 -A q ; Z is either OH or L 2 - Az ; Y is either OH or L 2: A y and X is either OH or L 2: A x In this specification L 2 As defined above, A q , A x , A y , Az Each of these is a clickable base, A q , A xAt least one of Ay or Az is Az If it exists, then the following formula:

[0143] [ka] (In the formula, payload and L1 are as defined above, Ap A is a complex carbohydrate precursor. q , A x , A y , Az (It is a clickable group that is complementary to either of the above.) (It has a payload precursor.) It can be prepared by carrying out a cyclic addition reaction between complex carbohydrate precursors having the specified properties.

[0144] As used herein, "clickable group" refers to a functional group that undergoes a cyclic addition reaction under conditions compatible with the cell binder, i.e., does not denature or otherwise degrade the polymer chain. Complementarity refers to the relationship between the clickable groups of the complex carbohydrate precursor and the payload precursor. Complementary clickable group pairs include strained cyclic systems and 1,3-dipole or tetrazine groups. Strained cyclic systems are represented by the following formula:

[0145] [ka] (In the formula, W 1 is either an alkyne or a trans double bond, for example, in the following formula:

[0146] [ka] Or, (in the formula, in the formula, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ Each of these is independent: none, H, F, Cl, Br, I, C 1~4 Alkyl, C1~4 Selected from alkoxy and aryl; and, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ One of the following is L 1 or L 2 It is fine to be that way, RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ One of the following is L 1 or L 2 If so, the remaining RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ One of the following is L 1 or L 2 Not; RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ Two or more of these can together form a ring; for example, R A1 and R A2、 and R A3 and R A4 Both can form aromatic rings, but in that case, R A1’ , R A2’ , R A3’ , and R A4’ None of them RA 1 RA 1’ RA 2 RA 2’ RA 3 RA3’ RA 4 , and RA 4’ Any of the L 1 or L 2 In this case, W may be CH2CH2; RA 1 RA 1’ RA 2 RA 2’ RA 3 RA 3’ RA 4 , and RA 4’ All of them are L 1 and L 2 Otherwise, W is given by the following formula:

[0147] [ka] (In the formula, L 1 / 2 is L 1 or L 2 (Represents one of the following) It may be a base that has)) It contains cyclooctine and trans-cyclooctene.

[0148] In some cases, a strained circulating system can be described by the following equation:

[0149] [ka] It has.

[0150] In some cases, a strained cyclic system can be expressed by the following equation: Suitable 1,3 dipoles and tetrazine include the following:

[0151] [ka] (In the formula, R H 1 and R H 2 (This is as defined above.) It is a trans-cyclooctene with the following properties:

[0152] In one embodiment, the complex carbohydrate precursor contains tetrazine and the payload precursor contains trans-cyclooctene, and vice versa. If the complex carbohydrate precursor contains azide, diazo, nitrone, azoxy, nitrile oxide, or cydonone, the payload precursor contains cyclooctin, and vice versa. q , A x , A y , A z , and A p By utilizing the different reactivity between different pairs of groups, a single sialoside can exist and bind to multiple payloads with high control. The reaction between the complex carbohydrate precursor and the payload precursor should preferably be carried out in a buffered aqueous solution such as phosphate, buffered saline (e.g., phosphate-buffered saline, Tris-buffered saline), citrate, HEPES, Tris, and glycine. The buffer should preferably be phosphate-buffered saline (PBS) or Tris buffer. The reaction can be carried out at a temperature of approximately 4°C to 50°C, more preferably 10°C to 45°C, even more preferably 20°C to 40°C, and most preferably 30°C to 37°C. The reaction can be carried out at a pH of approximately 5 to 9, preferably 5.5 to 8.5, and more preferably 6 to 8. Most preferably, the reaction can be carried out at a pH of approximately 7 to 8. In some cases, the first compound may contain a mixture of the 2,6 and 2,3 linkage sugar conjugate precursors shown above. In other embodiments, the sugar conjugate precursor may be substantially 2,6 linkage oligosaccharides only, or substantially 2,3 linkage oligosaccharides. In some embodiments, the sugar conjugate precursor may be at least 90%, at least 95%, at least 98%, or at least 99% of the 2,6 linkage oligosaccharides, while in other embodiments, the sugar conjugate precursor may be at least 90%, at least 95%, at least 98%, or at least 99% of the 2,3 linkage oligosaccharides.

[0153] In a preferred embodiment, the oligosaccharide of the sugar conjugate precursor can be bound to CBA via a β-N-glycosidic bond:

[0154] [ka] In certain embodiments, the cell-binding agent is an antibody, and the oligosaccharide is bound to the antibody via a β-N-glycosidic bond and an asparagine side chain:

[0155] [ka] In some cases, the GlcNAc moiety is conjugated to the antibody at the asparagine 297 (Asn297) residue, according to the EU index described in Kabat. In certain embodiments where y is 2, the GlcNAc moiety can be conjugated to both Asn297 residues in the Fc domain. In embodiments where y is 1, the GlcNAc moiety can be conjugated to either Asn297 residue in the Fc domain. If the antibody is modified by either chain extension or cleavage, the oligosaccharide can be conjugated to the asparagine residue corresponding to Asn297 in the unmodified antibody. In certain embodiments, the complex carbohydrate precursor is Q=L 2 -A q Characterized by, where each of X, Y, and Z is OH. In certain embodiments, the complex carbohydrate precursor is Q=H, Z=L 2 -A z Characterized by, where both X and Y are OH. In yet another embodiment, the complex carbohydrate precursor is Q=L 2 -A q Z=L 2 -A z Characterized by such that both X and Y are OH. In such a case, A q and A z They may be the same or different. For example, A q It can contain tetrazine, but A z This can include 1,3 dipole, for example, an azide, and vice versa. In other examples, A qIt can contain trans-cyclooctene, but A z It can contain cyclooctin.

[0156] The complex carbohydrate precursor is given by the following formula:

[0157] [ka] (In the formula, R fa , y, and CBA are as defined above, and the sialoside donor is given by the following formula:

[0158] [ka] (In the formula, Q, Z, Y, and X are as defined above, and P* is a nucleotide, such as uridine phosphate, guanosine phosphate, or cytidine phosphate.) It can be obtained by glycosylation of a disaccharide receptor that has [a specific characteristic].

[0159] Unless otherwise specified, the term "phosphate" includes any number of consecutive phosphate ester bonds, such as monophosphate, diphosphate, triphosphate, etc. In preferred embodiments, the sialoside donor is of the following formula:

[0160] [ka] It holds.

[0161] The disaccharide acceptor and sialoside donor can be contacted by at least one sialyltransferase for a sufficient time under conditions sufficient to form a sugar-conjugated precursor. The sialyltransferase may be derived from mammals, fish, amphibians, birds, invertebrates, or bacteria. In one embodiment, the sialyltransferase is α-(2,3,)-sialyltransferase. In another embodiment, the sialyltransferase is α-(2,6,)-sialyltransferase. In yet another embodiment, the sialyltransferase is α-(2,8,)-sialyltransferase. In a preferred embodiment, the sialyltransferase is α-(2,6,)-sialyltransferase, preferably β-galactoside α-(2,6,)-sialyltransferase 1 (ST6Gal1). In a preferred embodiment, the sialyltransferase is a mammalian sialyltransferase. In other embodiments, sialyltransferase rat β-galactosamide α-2,6-sialyltransferase 1 (ST6Gal1); Pasteurella multocida α-(2,3,)-sialyltransferase; or CMP-N-acetylneuraminic acid-β-galactosamide-α-2,3-sialyltransferase (ST3Gal IV).

[0162] Glycosylation with sialocide donor can be carried out in a suitable buffer such as phosphate, buffered saline (e.g., phosphate-buffered saline, Tris-buffered saline), citrate, HEPES, Tris, or glycine. Suitable buffers are known in the art, and the buffer is preferably phosphate-buffered saline (PBS) or Tris buffer. Glycosylation is preferably carried out at a temperature in the range of 4°C to about 50°C, more preferably in the range of 10°C to about 45°C, even more preferably in the range of 20°C to about 40°C, and most preferably in the range of 30°C to about 37°C. Glycosylation can be carried out at a pH in the range of about 5 to about 9, preferably about 5.5 to about 8.5, more preferably about 6 to about 8. Most preferably, glycosylation can be carried out at a pH in the range of about 7 to about 8.

[0163] In one embodiment, the disaccharide receptor can be connected to the CBA via a β-N-glycosidic bond:

[0164] [ka] In certain embodiments, the cell-binding agent is an antibody, and the disaccharide receptor is bound to the antibody via a β-N-glycosidic bond and an asparagine side chain:

[0165] [ka] In some cases, the GlcNAc moiety is conjugated to the antibody at the asparagine 297 (Asn297) residue, according to the EU index shown in Kabat. In certain embodiments where y is 2, the GlcNAc moiety can be conjugated to both Asn297 residues in the Fc domain. In embodiments where y is 1, the GlcNAc moiety can be conjugated to one of the Asn297 residues in the Fc domain. If the antibody is modified by either chain elongation or cleavage, the oligosaccharide can be conjugated to the asparagine residue corresponding to Asn297 in the unmodified antibody. The disaccharide receptor is represented by the following formula:

[0166] [ka] (In the formula, R fa (By definition above, y and CBA are steps in which the cleaved N-glycan receptor is glycosylated with a galactose donor.) To obtain cleaved N-glycan receptors, this can be prepared by a process that includes an antibody remodeling step.

[0167] In one embodiment, the cleaved N-glycan receptor can bind to CBA via a β-N-glycosidic bond:

[0168] [ka] In certain embodiments, the cell-binding agent is an antibody, and the GlcNAc residue (with or without C-6 fucose) is bound to the antibody via a β-N-glycosidic bond through the asparagine side chain:

[0169] [ka] In one preferred embodiment, R fa The GlcNAc receptor is characterized when the receptor is fucose, preferably L-fucose, and more preferably α-L-fucose. In one embodiment, the GlcNAc residue is conjugated to the antibody at the asparagine 297 (Asn297) residue according to the EU index shown in Kabat. In a particular embodiment where y is 2, the GlcNAc residue can be conjugated to both Asn297 residues in the Fc domain. In an embodiment where y is 1, the GlcNAc residue can be conjugated to either Asn297 residue in the Fc domain. If the antibody is modified by either chain extension or cleavage, the oligosaccharide can be conjugated to the asparagine residue corresponding to Asn297 in the unmodified antibody.

[0170] The cleaved N-glycan acceptor can be obtained by modifying any suitable antibody as disclosed herein. In some embodiments, the modification is carried out using an endoglycosidase, for example, an endoglycosidase classified in EC3.2.1.96. In some embodiments, the endoglycosidase may be endo-β-N-acetylglucosaminidase D (endoglycosidase D, endo-D, or endo-D), endo-β-N-acetylglucosaminidase H (endoglycosidase H, endo-H, or endo-H), endoglycosidase S (EndoS, Endo-S, or end-S), endo-β-N-acetylglucosaminidase M (endoglycosidase M, endo-M, or endo-M), or endo-β-N-acetyl Examples include glucosaminidase LL (endoglycosidase LL, EndoLL, Endo-LL or endo-LL), endo-β-N-acetylglucosaminidase F1 (endoglycosidase F1, endo-F1 or endo-F1), endo-β-N-acetylglucosaminidase F2 (endoglycosidase F2, endo-F2 or endo-F2), and endo-β-N-acetylglucosaminidase F3 (endoglycosidase F3, endo-F3 or endo-F3). In some embodiments, a combination of two or more endoglycosidases can be used in the remodeling stage. For example, some endoglycosidases may be a combination of endoglycosidases with different substrate specificities classified in EC3.2.1.96. Typical combinations include endoglycosidase D and endoglycosidase S; endoglycosidase S and endoglycosidase LL; endoglycosidase D and endoglycosidase LL; endoglycosidase D and endoglycosidase H; endoglycosidase S and endoglycosidase H; endoglycosidase F1 and endoglycosidase F2; endoglycosidase F1 and endoglycosidase F3; endoglycosidase F2 and endoglycosidase F3; endoglycosidase D, endoglycosidase S and endoglycosidase LL; endoglycosidase D, endoglycosidase S and endoglycosidase H; and endoglycosidase D, endoglycosidase S and endoglycosidase F1.

[0171] Remodeling can be carried out in a suitable buffer such as phosphate, buffered saline (e.g., phosphate-buffered saline, Tris-buffered saline), citrate, HEPES, Tris, or glycine. Suitable buffers are known in the art, and the buffer is preferably phosphate-buffered saline (PBS) or Tris buffer. Remodeling is preferably carried out at a temperature in the range of 4°C to about 50°C, more preferably in the range of 10°C to about 45°C, even more preferably in the range of 20°C to about 40°C, and most preferably in the range of 30°C to about 37°C. Remodeling can be carried out at a pH in the range of about 5 to about 9, preferably about 5.5 to about 8.5, more preferably about 6 to about 8. Most preferably at a pH in the range of about 7 to about 8. In one embodiment, a GlcNAc residue (with or without C-6 fucose) can be bound to Asn297 (either one or both of the heavy chains), allowing the antibody to be reconstituted so that no other glycan structures are present on the antibody.

[0172] The cleaved N-glycan acceptor can be purified according to conventional techniques or used directly for galactosylation. The disaccharide acceptor described above can also be prepared by combining the cleaved N-glycan acceptor, a galactosyl donor, and a galactosyltransferase. Suitable galactosyl donors include galactosyl nucleotides containing UDP-galactose.

[0173] The complex carbohydrates disclosed herein may be provided to patients in need in a pharmaceutical composition comprising the complex carbohydrate and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be any suitable pharmaceutically acceptable carrier, which may be one or more compatible solid or liquid fillers, diluents, other excipients, or encapsulating materials suitable for administration to human patients or animal subjects (e.g., physiologically acceptable carriers or pharmacologically acceptable carriers). This composition may contain pharmaceutically acceptable additives. Examples include buffering agents such as acetic acid, citric acid, boric acid, and phosphoric acid in the salt, and preservatives such as benzalkonium chloride, chlorobutanol, parabens, and thimerosal.

[0174] A composition suitable for parenteral administration conveniently contains a sterile aqueous formulation of the composition of the present invention, which is preferably isotonic with the recipient's blood. This aqueous formulation can be formulated according to known methods using appropriate dispersants or wetting agents and suspension agents. Alternatively, a sterile injectable formulation may be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Acceptable solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile fixative oils are commonly used as solvents or suspension media. For this purpose, mild fixative oils such as synthetic mono- or di-glycerides can also be used. Furthermore, fatty acids such as oleic acid can be used in the preparation of injectable formulations. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administration are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. The preparation of the pharmaceutical compositions of the present invention and their various routes of administration can be carried out according to methods well known in the art. For example, see Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000; and Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978. Useful delivery systems in the context of the present invention include time-release, delayed-release, and sustained-release delivery systems, in which the composition of the present invention is delivered prior to sensitization of the site to be treated and over a sufficient period of time. The composition of the present invention can be used in combination with other therapeutic agents or treatments. Such systems can avoid repeated administration of the composition of the present invention, thereby increasing convenience for subjects and physicians, and may be particularly suitable for certain compositions of the present invention.

[0175] Many types of release delivery systems are available and known to those skilled in the art. Suitable release delivery systems include polymer base systems such as poly(lactide-glycolide), copolyoxalate, polycaprolactone, polyesteramide, polyorthoester, polyhydroxybutyric acid, and polyanhydride. Microcapsules of the above polymers containing drugs are described, for example, in U.S. Patent No. 5,075,109. Delivery systems include non-polymer systems such as cholesterol, cholesterol esters, lipids including sterols such as fatty acids, or neutral fats such as mono-di and triglycerides; hydrogel release systems; silastic systems; peptide-based systems; wax coatings; compressed tablets using conventional binders and excipients; and partial fusion implants. Specific examples include, but are not limited to, (a) erosion systems in which the active composition is contained in the form of a matrix, as described in U.S. Patents 4,452,775, 4,667,014, 4748034, and 5,239,660, and (b) diffusion systems in which the active ingredient penetrates from a polymer at a controlled rate, as described in U.S. Patents 3,832,253 and 3,854,480. Furthermore, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

[0176] Generally, the complex carbohydrates disclosed herein are provided in appropriate packaging, e.g., vials, pouches, ampoules, and / or any container suitable for therapeutic or detection methods. Kit components may be provided as concentrates (including lyophilized compositions) which may be further diluted before use or provided at the concentration of use.

[0177] [Examples] The following examples are for illustrative purposes only and are not intended to limit the scope of the invention in any way. Reagents and materials Unless otherwise noted, all materials were obtained from Sigma-Agenta. Cytidine-5'-(CMP-Neu5Ac9N3) and recombinant rat α-(2,6,)-sialyltransferase (GFP-ST6GalI) were prepared according to the previous report at http: / / dx.doi.org / 10.1002 / anie.201307095 (5-acetamide-9-azido-3,5,9-trideoxy-β-D-glycero-D-galacto-2-nonunlopyranosilonic acid monophosphate). Endo-BCN-PEG4-acid can be prepared according to the procedure described on page 142 of International Publication No. 2016 / 053107 and is also available from many commercial suppliers.

[0178] [ka] End-BCN-PEG4 [Examples]

[0179] Combining clickable payloads A cytotoxic warhead containing a single primary amine group (named WH-NH2 herein) was conjugated to End-BCN-PEG4 as follows: WH-NH2 (600 mg, 1.0 eq), Endo-BCN-PGE4-acid (1.2 eq), and EDCl-HCl (1.2 eq) were incorporated into DCM (15 vol, 2% MeOH) and stirred at 0-5°C. Once the reaction was complete, the reaction was rapidly cooled with purified water (10 vol). The aqueous layer was separated, the organic phase was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure to obtain crude WH-NH-Endo-BCN-PEG4 (650 mg, 93.2%, 73.57% HPLC purity). Crude WH-NH-Endo-BCN-PEG4 (400 mg) was purified by RP-HPLC (C18, MeCN:H2O), and the products containing the fractions were combined and freeze-dried to obtain WH-NH-Endo-BCN-PEG4 as a white solid (130 mg, 33%, 94.61% HPLC purity).

[0180] [ka] WH-NH-Endo-BCN-PEG4 [Examples]

[0181] CMP-Neu5N 3 and CMP-Neu9N 3 synthesis Tris-HCl buffer (100 mM, pH 8.9, 20 mM gCl) containing sodium pyruvate (10.5 mg, 0.095 mmol) and CTP (10 mg, 0.019 mmol). 2、 Sialic acid aldolase (0.2 U / μL, 5 μL) and CMP-sialic acid synthase (0.2 U / μL, 5 μL) were added to a mixture of N-azidoacetyl-D-mannosamine (5 mg, 0.019 mmol) in 1.9 mL. Three tubes were used. 7℃ The mixture was incubated, and the reaction progress was monitored by TLC (EtOH:aq.NH4HCO3 (1M) 7:3, v:v), indicating completion of the reaction after 5 hours. EtOH (3 mL) was added, the precipitate was removed by centrifugation, and the supernatant was concentrated under reduced pressure. The residue was redissolved in distilled water (500 μL), lyophilized to obtain the crude product, and spread onto a biogel fine-grain P-2 column (50 * 1 cm, dark, 4°C, eluted with 0.1 M NH4HCO3). The product was detected by TLC, and appropriate fractions were combined and lyophilized to obtain CMP-Neu5N3 as an amorphous white solid (10.1 mg, 81%).

[0182] [ka] CMP-Neu9N3 was prepared according to the reported procedure. CTP (126 mg, 0.24 mmol) was added to a solution of 5-acetamido-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-2-nonulosonic acid (50 mg, 0.15 mmol) in Tris-HCl buffer (0.1 M, 9 mL, pH 8.9) containing MgCl2 (20 mM). Recombinant CMP-sialic acid synthase (4.0 U) from N. meningitis and inorganic pyrophosphatase (2.0 U) from S. cerererisiae were added, and the reaction mixture was incubated at 37°C with shaking. The progress of the reaction was monitored by TLC (isopropanol: 20 mM NH4OH, 4:1, v:v), and completion of the reaction was indicated after 3 hours. Ethanol (80 mL) was added, and the mixture was kept on ice for 2 hours before centrifugation. The supernatant was decanted, and the pellet (mostly inorganic salts) was resuspended in EtOH (30 mL), cooled on ice for 1 hour, and centrifuged. The combined ethanol extract was concentrated under vacuum to obtain the crude substance (168 mg). When ethanol (1.8 mL) was slowly added to the substance dissolved in H2O (0.2 mL), a precipitate immediately formed. The mixture was left on ice for 2 hours. Next, after centrifugation, the supernatant was removed, and the white pellet was dried and purified using a column of ultrafine biogel P-2 eluted with 0.1 M NH4HCO3 at 4°C. Appropriate fractions were detected by UV and TLC (as above), collected, concentrated under vacuum (bath temperature <25°C), and freeze-dried to obtain CMP-Neu9N3 (60 mg, 62%).

[0183] [ka] [Examples]

[0184] Glycan remodeling Analysis of glycopeptides by trypsin digestion of antibodies Aliquotes of IgG antibody were dried in a Speed ​​Vac (Savant SC110), redissolved in ammonium bicarbonate buffer (50 mM, pH 8.4), and heated at 100°C for 5 minutes to denature the glycoprotein. After the mixture cooled to room temperature, trypsin (trypsin / IgG = 1 / 30, w / w) was added, the solution was incubated at 37°C for 22 hours, and then heated at 100°C for 5 minutes to inactivate the trypsin. This solution was passed through a C18 reversed-phase cartridge, washed with 5% aqueous acetic acid, and eluted with a 2-propanol / 5% acetic acid (20-100%) gradient to obtain glycopeptides, which were then analyzed using an LCMS-IT-TOF mass spectrometer (Shimadzu Corporation) equipped with an XBridge-BEH amide-HILIC column (Waters, Milford, MA, USA; 2.1 × 150 mm, particle size 3.5 μm). These separations were performed at 20°C and a flow rate of 0.16 ml / min using mobile phase A, consisting of 100 mM ammonium formate in water (adjusted to pH 3.4-3.6 with formic acid), and mobile phase B, as pure ACN. Native intact IgG analysis In the preliminary analysis, the sample was desalted using a ZEBA spin column, diluted to 2 mg / ml, and injected as 0.5 uL (=1 ug). The sample was run / injected at 70°C for 10 minutes using an Agilent Infinity LC mounted on an Acquity 1290 angstrom C18 2.1x50 mm with a gradient of 20-40% B (=70% IPA / 20% ACN / 10% H2O / 0, 1% FA) versus A (0, H2O with 1% FA). The detector was an Agilent 6560 IonMobility Q-TOF LC / MS, and only the Q-TOF function was used for this purpose. Post-run analysis and deconvolution were performed using Agilent's Bioconfirm software.

[0185] General procedure for correcting IgG using App2 (Figure 2) Endo S. Treatment Endo S cloned from Streptococcus pyogenes was used to trim IgG glycans, which were then overexpressed as a fusion with the chitin-binding domain of E. coli (New England BioLabs). IgG antibody (10 mg / mL) in 30 mM histidine, 200 mM sorbitol, and 0.02% Tween-20 was mixed with Endo S (0.13 mL, 100 kU / mL) in 10 mM Tris, 25 mM NaCl, 2.5 mM EDTA, 2.5 mM CaCl2, and 25 mM sodium acetate. The resulting solution was incubated at 37°C for approximately 48 hours, then purified using a Protein A Sepharose column (GE Healthcare), buffer was changed, and the solution was concentrated into 1.2 mL of 50 mM OPS containing 20 mM nCl2. Galactosylation of IgG Galactosylation of IgG containing cleaved N-glycans was achieved by adding β-1,4-galactosyltransferase (200 μg / mL) to the substance obtained from Endo S treatment with 50 mM OPS, 20 mM nCl2, 10 mM UDP-galactose, pH 7.2, 80 μg / mL BSA, and 85 U / mL calf alkaline phosphatase, and incubating at 37°C for 70 hours. To ensure complete galactosylation, another aliquot of UDP-galactose and galactosyltransferase was added to the reaction mixture and incubated for a further 24 hours at 37°C. The galactosylated IgG was purified using a Protein A Sepharose column, and the solution was replaced with 50 mM cacodylate at pH 7.6 using an Amicon 10 kDa cutoff spin concentrator (Millipore). IgG sialylation Siarylation of galactosylated IgG was performed using 50 mM cacodylic acid, 14 mg / mL IgG, and 8 mM CMP-Neu5N at pH 7.6. 3、The preparations were tested with 90 μg / ml BSA, 90 U / mL calf enteric alkaline phosphatase, and 0.4 mg / mL GFP-ST6GalI, incubated at 37°C for 4 days, purified using a Protein A Sepharose column, and buffered with 50 mM cacodylate. The degree of sialylation was monitored by LC-MS using a Shimadzu LCMS-IT-TOF mass spectrometer, as previously described. After incubation every 48 hours, the samples were buffered with 50 mM cacodylate at pH 7.6 using an Amicon 10 kDa cutoff spin concentrator to remove the inhibitors CMP and ST6GalI, and further aliquots of CMP-Neu5N3 and α2-6 sialyltransferase were returned to this washed preparation. The key discovery was the unexpected ability of wild-type human β4GalT1 galactosyltransferase to transfer galactose residues to α1-6 fucosylated GlcNAc residues. This reaction does not occur in nature. Furthermore, it was found that the resulting disaccharide can be further modified by adding azide-modified sialic acid via ST6Gal1 sialyltransferase. [Examples]

[0186] Conjugate with clickable payloads In Example 3, 210 mg / ml of Her was conjugated to 7.5 molar equivalents of WH-NH-Endo-BCN-PEG4 (Example 1) (10 mM stock in DMA) in 50 mM cacodylate buffer pH 7.6, and DMA was added to reach the final cosolvent level of 20% v / v. After incubation overnight in a 20°C water bath, the mixture was purified by PLRP. A DAR of 1.8 was achieved by PLRP. The resulting complex carbohydrate is referred to as "Her-App2" in this specification. [Examples]

[0187] Preparation of bitactile antibody-drug conjugates N-linked oligosaccharides on Herceptin antibody were remodeled according to the method described in Non-Patent Literature 11. See Figure 1. 9.2 mg / ml of modified Her2 (Example 3) in 50 mM cacodylate buffer pH 7.6 was conjugated to a final Co solvent level of 20% v / v by adding 20 molar equivalents of WH-NH-Endo-BCN-PEG4 (Example 1) (10 mM stock of DMA, structure shown in Figure 1) and DMA, and the conjugation reaction was incubated in a water bath at 20°C for 66 hours. DAR by PLRP of 1.4 was achieved. The resulting complex carbohydrate is referred to as "Her-App1" in this specification. The activity of recombinant sialyltransferase ST6Gal1 antibodies against the α(1,3)- and α(1,6)-arms of the bifurcated N-glycan in the Fc region can be differentiated by controlling the ratio of CMP-sialic acid to antibody. This allows the ADC to have either DAR2 or DAR4. However, careful control of the required reaction stoichiometry will affect lot-to-lot product reproducibility. [Examples]

[0188] Properties of complex carbohydrates physical properties Her-App1 and Her-App2 were analyzed by hydrophobic interaction chromatography (HIC). This was performed using a MabPac HIC-Butyl, 5 μm, 4.6 × 100 mm column (Thermo #882558, lot 01425138, serial number 001303) with a MabPac HIC-Butyl, 5 μm, 4.6 × 10 mm guard cartridge (Thermo #882559, lot 1425011). Mobile phase A was 1.5 M (NH4)2SO4, 25 mM NaPO4 (pH 7.4), and mobile phase B was 80% 25 mM NaPO4 (pH 7.4), 20% CH3CN. The assay was performed at a flow rate of 0.8 ml / min and a column temperature of 25°C. A 10 μl sample load of 1 mg / ml was used for analysis. HIC showed clear differences between the two ADCs; Her-App1 separated into multiple hydrophobic species, while Her-App2 eluted as a single hydrophilic peak (see Figure 4). The increased hydrophilicity of Her-App2 relative to Her-App1 is, at first glance, surprising given that Her-App2 has significantly fewer sugar residues than Her-App1 (compare Figures 2 and 3). Sugar residues are highly hydrophilic regions, suggesting that conjugates with more sugar residues are more hydrophilic. The fact that this is not the case suggests that more complex interactions are occurring between the antibody, oligosaccharide, and drug linker elements of the ADC. In vitro binding to Her2 Her2 is a congener antigen of Herceptin antibodies. The binding of Her-App1 to Her-App2 was determined by ELISA. Maxisorp ELISA plates were coated with 0.5 μg / mL recombinant human Her2 at room temperature and then blocked with 3% BSA. Sample titrations were prepared in quadrant dilutions between 66.6 and 0.016 nM in quantitative buffer (0.1% BSA / 0.05% tween). The samples were then incubated on antigen-coated plates for 1 hour. A mouse anti-human antibody conjugated to HRP (SanquinM 1328) was used for detection. After incubation for 1 hour, the samples were washed, the detection agent TMB was added for 10 minutes, and the reaction was stopped with HCl. Binding absorbance data were acquired using a 450 nm Spectramax plate reader. For comparison, Her-C220 [an unconjugated monoclonal antibody against the HIV-1 protein; used as a control herein] and B12 were also evaluated for Her2 binding.

[0189] [Table 1] The two ADCs coupled to Her2 with similar affinity.

[0190] In vitro cytotoxicity The in vitro cytotoxicity of Her-App1 and Her-App2 against Her2+ve N87 cells was measured. A "thaw and transfer" cytotoxicity test was used to determine cytotoxicity, with N87 cells harvested from cryogenic storage and placed on EDGE plates in a 5x10⁶ configuration. 4 cells / mL(5x10 3 Cells were seeded (per well) and then incubated at 37°C / 5%CO2 / absolute humidity for a minimum of 2 hours. Eleven points of the test and control samples were prepared for sequential titration, once every four times, from 500 nM to 0.4768 pM in two stages, with the final titration being a negative control. The titrated samples were added to EDGE plates containing cells and incubated at 37°C / 5%CO2 / absolute humidity for 5 days. Celltiter Aqueous One solution was added, and the plates were incubated one last time at 37°C / 5%CO2 / absolute humidity. Absorbance was then measured at 490 nm using a SpectraMax plate reader. For comparison, the cytotoxicity of "Her2xADC" (Her2-C220 bound to tesirin at the C220 residue) and B12-C220-SG3249 (B12 antibody bound to tesirin at the C220 residue) was also evaluated.

[0191] [Table 2] Her-App1 and Her-App2 exhibited similar cytotoxicity to each other and were found to have similar cytotoxicity to the benchmark Her2xADC. Significantly less cell killing was observed with non-Her2-bound B12 control ADC. In vivo efficacy In a breast cancer Her2+ve BT474 xenograft model, the in vivo efficacy of Her-App1 and Her-App2 conjugates was measured. For comparison, the in vivo efficacy of "Her2xADC" was also evaluated. Female severe combined immunodeficiency mice (FoxChase SCID®, CB 17 / Icr-Prkdcscid / IcrIcoCrl, Charles River) were 10 weeks old, and their body weight (BW) ranged from 16.1g to 21.8g on day 1 of the study. On the day of tumor transplantation, 1 mm was implanted in each test mouse. 3 A BT 474 fragment was implanted subcutaneously in the right flank, with an average size of 100 mm within the target range. 3 From 150mm 3 Tumor growth was monitored as we approached the site. The tumor was measured in two dimensions using calipers, and its volume was calculated using the following formula. Tumor volume (mm 3 )=w 2 xl / 2 In this specification, w = width, l = length, and the unit is mm. Tumor weight is defined as 1 mg equal to 1 mm of tumor volume. 3 It can be estimated by assuming that it corresponds to [this]. 36 days after tumor transplantation (Day 1 of the experiment), the animals were divided into groups of 10 mice, and the tumor volume of each group was measured from 75 to 172 mm². 3 , the average tumor volume was 119 to 121 mm 3 The drug was administered intravenously as a single dose (qd×1) via tail vein injection on the first day of the study. The dose was 0.2 mL per 20 g (10 mL / kg) of body weight, and was proportional to the body weight of each animal. Tumors were measured twice a week using a caliper, and each animal's tumor reached an endpoint volume of 1000 mm³. 3 Euthanasia was performed at the earlier of the following two points: when the target was reached, or at the end of the experiment (day 59). The results are shown in Figure 4. The minimum effective dose (MED) for Her2xADC and Her-App1 was >0.6 mg / kg, while the MED for Her-App2 was determined to be 0.3 mg / kg. Tolerability: Rat toxicity test Her2xADC, Her-App1, and Her-App2 were evaluated in tolerability studies in rats that received a single intravenous dose. Male Sprague Dawley rats (3 rats per group) were administered Her-App1 4 mg / kg, Her-App2 2 mg / kg, and Her-App1 4 mg / kg on day 1, and necropsy was performed on day 21 post-administration. Body weight and food intake were frequently monitored through biological sampling for clinicopathological examination (blood on days 8 and 21) and repeated sampling for pharmacokinetic studies. At necropsy, the weight of selected organs was measured, and macroscopic observation was performed while preserving them for potential histopathological examination. Her2xADC was evaluated at 1.5 mg / kg, and a single intravenous injection into male Sprague Dawley rats was associated with decreased overall body weight gain in relation to decreased food intake (overall body weight gain was 39% lower). White blood cell count decreased on day 8 (-61%), with evidence of recovery by day 21. Necropsy revealed decreased weight of the thymus, spleen, testes, and prostate / seminal vesicles, and increased weight of the adrenal glands. Her-App1 was poorly tolerated at 4 mg / kg, and two out of three animals were euthanized prematurely 11 days after administration. These animals experienced significantly reduced weight gain, and there was no expected weight gain after administration. Several hematological parameters decreased significantly on day 8 (reticulocytes (-93%), leukocytes (-86%), platelets (-66%)), and there was no evidence of recovery. Her-App2 was clinically well tolerated at 2 and 4 mg / kg. Body weight gain decreased in a dose-dependent manner (overall body weight gain was 55% lower at 4 mg / kg), consistent with decreased food intake. Several hematological parameters decreased on day 8 (reticulocytes (-52%), leukocytes (-68%), platelets (-22%)), with evidence of recovery by day 21. Necropsy revealed dose-dependent decreases in thymus, liver, and spleen weight and increases in lung weight, and two animals had pale kidneys at 4 mg / kg. The maximum tolerated dose (MTD) of Her2xADC was 1.5 mg / kg (the highest dose tested). The maximum tolerated dose (MTD) of Her-App1 was less than 4 mg / kg. The maximum tolerated dose (MTD) of Her-App2 was 4 mg / kg. therapeutic index The therapeutic index (TI) of ADCs can be calculated by first determining the human equivalent doses of MED and MTD, and then dividing the HED of MTD by the HED of MED, as shown below.

[0192] [Table 3] MED: Minimum Effective Dose in Mouse MTD: maximum tolerated dose HED: Human Equivalent Dose TI: Therapeutic Index Her-App2 shows more than twice the therapeutic index of Her-PL1603-App1. Her-App2 exhibits approximately six times the therapeutic index of Her2xADC.

[0193] Pharmacokinetics (PK) of Her-App1 and Her-App2 in rats Plasma samples and specimens were collected from rats that received a single dose of Her-App1 and Her-App2 at 2 mg / kg or 4 mg / kg at 1, 3, 6, 48, 72, 168, 336, and 480 hours after administration. The samples were analyzed for total human IgG and WH-conjugated IgG as described in Zammarchi Blood vol 131(10)1094-1105 2018. Figure 5A shows the equivalent PK profiles of Her2-App1 against 4 mg of total IgG and WH-IgG (i.e., warhead-bound IgG), demonstrating the high stability of the conjugate. Figure 5B shows equivalent PK profiles of Her2-App2 for both 2 mg and 4 mg total IgG and WH-IgG, indicating that the conjugate is highly stable. Other comments regarding the property A further advantage of "Approach 2," as described in Examples 1-4, is that it is easier to control DAR in Approach 2. In previous approaches using intact glycans, controlling DAR in Approach 2 was more difficult and required careful control of reaction conditions. Furthermore, Approach 2 eliminates the Fc (gamma) receptor activity, which is a benefit for many ADC applications. [Examples]

[0194] Further conjugates

[0195] [ka] The remodeling antibody from Example 3 is mixed with meitansine DIBO or vinblastine DIBO in DMF in cacodylate buffer at pH 7.6. The mixture is shaken in a shaker at room temperature for 2 hours, and excess DIBO reagent is removed by washing with cacodylate buffer or PBS buffer using a 7 kDa cutoff Zeba spin column (thermoscientific). Conjugate Each of the above-mentioned mytansine and vinblastine drug linkers was conjugated to the Her2 antibody following the general procedure described in Example 4 above. In both cases, complete conversion of the modifications was observed by native intact IgG analysis (i.e., DAR=2). [Examples]

[0196] [ka] 4-(((1S,2R)-1-benzamide-3-(((4S,4aS,6R9S,11S,12S,12aR12bS)-6,12b-diacetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxo-9-yl)oxy)-3-oxo-1-phenylpropane-2-yl)oxy)-4-oxobutanoic acid(8-2)

[0197] [ka] A reaction mixture of 8-1 (0.05 g, 0.06 mmol) and succinic anhydride (0.076 g, 0.76 mmol) in 1.2 mL of pyridine was stirred at room temperature for 3 hours. After 3 hours, the pyridine was evaporated to dryness under vacuum. The residue was then treated with 2 mL of water, stirred for 20 minutes, and filtered. The resulting precipitate was dissolved in acetone, water was slowly added, and the fine crystals of the product were collected. This yielded 0.048 g (86%) of 8-2.

[0198] [ka] Bicyclo[6.1.0]non-4-in-9-ylmethyl(4-nitrophenyl)carbonate(8-3)

[0199] [ka] To a CH2Cl2 solution (10 mL) of ((1R, 8S, 9r)-bicyclo[6.1.0]non-4-in-9-ylmethanol (100 mg, 0.66 mmol), pyridine (134.70 μL, 1.66 mmol) and 4-nitrophenyl chloroformate (200 mg, 1 mmol) were added. After stirring at room temperature for 3 hours, the reaction mixture was quenched with a saturated ammonium chloride solution (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organic phase was dried over MgSO4 and concentrated under vacuum. The residue was further purified by column chromatography on silica gel (Âi:hexane, 1:5) to obtain the target product 8-3 (162 mg, 77%) as a white solid.

[0200] [ka] ((1R, 8S, 9r)-Bicyclo[6.1.0]non-4-in-9-ylmethyl(2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate(8-4)

[0201] [ka] Et3N (339 μL, 1.945 mmol) was added to a stirred solution of 8-3 (150 mg, 0.389 mmol) and tris(ethylene glycol)-1,8-diamine (569 μL, 3.89 mmol) in CH2Cl2 (10 mL). The reaction mixture was stirred for 3 hours, after which the solvent was removed under reduced pressure. The residue was purified by flash chromatography on latrobeads (MeOH / CH2Cl2, 5 to 25%, v / v) to obtain compound 8-4 as a pale yellow liquid (116 mg, 92%).

[0202] [ka] (4S,4aS,6R9S,11S,12S,12aR12bS)-9-(((19R)-19-((S)-Benzamido(phenyl)methyl)-1-(Bicyclo[6.1.0]non-4-in-9-yl)-3,14,17trioxo-2,7,10,18tetraoxa-4,13diazycosane-20-oil)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(8-5)

[0203] [ka] A mixture of 8-2 (5 mg, 0.0052 mmol) and 8-4 (2.1 mg, 0.0062 mmol) was dissolved in anhydrous DMF (1 mL). N,N-diisopropylethylamine (2.73 μL, 0.0157 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 3 mg, 0.00786 mmol) were added sequentially, and the reaction mixture was stirred at room temperature for 2 hours. After stirring at room temperature for 2 hours, TLC showed a complete reaction. The solvent was evaporated under reduced pressure, and the crude product was purified by silica gel chromatography using siRNA:hexane (5 to 15%, v / v) as the mobile phase to obtain pure 8-5 as a white solid (6.5 mg, 98%).

[0204] [ka]

[0205] [ka] Conjugate The clickable drug linker (compound 8-5) described above was conjugated to the Her2 antibody following the general procedure described in Example 4 above. Complete conversion of the modification was observed by native intact IgG analysis (i.e., DAR=2). [Examples]

[0206] [ka] 1-(4-methoxyphenyl)-2-(2-methylprop-1-en-1-yl)-4-oxoazetidine-3-yl acetate (9-1)

[0207] [ka] To a solution of 4-methoxyaniline (6.14 g, 50 mmol) in dry CH2Cl2 (50 ml), 3-methylbuto-2-enal (4.62 g, 55 mmol) and 4-angstrom molecular sieve (5 g) were added under N2 conditions. The mixture was then stirred at room temperature for 4 hours. After complete reaction, the molecular sieve was removed by filtration, and the solvent was removed under vacuum. The residue was dissolved in dry CH2Cl2 (50 ml) with TEA (7.58 g, 75 mmol) at -78°C. Dichloro-di-oxoethyl acetate (8.16 g, 60 mmol) was added to the solvent over 10 minutes. The reaction was then slowly warmed to room temperature. After 12 hours, the solvent was washed with saturated NH4Cl solvent, and the aqueous phase was extracted with CH2Cl2 (50 ml x 3). The combined organic phase was washed with brine, dried on MgSO4, concentrated, and then purified by silica gel column using EA:Hex (20:1~4:1) to obtain a pale yellow solid in 69% yield.

[0208] (2S,3R)-1-(4-methoxyphenyl)-2-(2-methylprop-1-en-1-yl)-4-oxoazetidine-3-ylacetic acid(9-1(+))

[0209] [ka] To 180 ml of 0.2 M sodium phosphate buffer (pH=7.4) containing (9-1) acetate (14.50 g, 50 mmol) of (9-1) (14.50 g, 50 mmol), 20 ml of acetonitrile was added, followed by 10 g of "PS Amano" lipase. The mixture was then vigorously stirred at 50°C. After 48 hours, 、1 ¹H NMR showed that the conversion rate of the starting material was 50%. The reaction mixture was filtered through Celite and EA (250 ml) *Extraction was performed using method 3). The combined organic phase was dried over Na2SO4 and concentrated. The crude product was purified by silica gel column using EA:Hex (20:1-4:1) to obtain (2S,3R)-1-(4-methoxyphenyl)-2-(2-methylprop-1-en-1-yl)-4-oxoazetidine-3-yl acetate (1(+)) as a white solid in 48% yield (97% ee). It was reacted again with "PS Amano" (half 5g) under the same conditions and further purified in a two-step yield of 43% (98.9% ee). (3R4S)-3-hydroxy-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)azetidine-2-one(9-2)

[0210] [ka] To a solution of potassium hydroxide (0.09 g, 1.6 mmol) in 1 ml of water and 3 ml of THF, (2S,3R)-1-(4-methoxyphenyl)-2-(2-methylprop-1-en-1-yl)-4-oxoazetidine-3-ylacetic acid (9-1(+)) (0.289 g, 1 mmol) was added at 0°C. The mixture was then warmed to room temperature and stirred for 3 hours. After completion, the solvent was washed with brine and extracted with EA (5 ml * 2). The combined organic phase was dried over anhydrous Na2SO4, concentrated, and purified by silica gel column using EA:Hex (4:1~1:1) to obtain (3R4S)-3-hydroxy-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)azetidine-2-one (9-2) as a white solid (yield 98%).

[0211] (3R4S)-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one(9-3)

[0212] [ka] To a 10 ml DMF solution of (3R4S)-3-hydroxy-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)azetidine-2-one (9-2) (2.47 g, 1 mmol), Et3N (1.5 g, 1.5 mmol)4-dimethylaminopyridine (1.22 g, 1 mmol) was added. Next, TIPSCl (2.12 g, 1.1 mmol) was added over 10 minutes. The mixture was stirred at room temperature for 3 hours. After completion, EA (50 ml) was added, and the solvent was replaced with water (10 ml). * 3) was washed with brine. The organic phase was dried over anhydrous Na2SO4, concentrated, and purified by silica gel column using EA:Hex (30:1~8:1) to obtain (3R4S)-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one (9-3) as a white solid (yield 97%).

[0213] (3R4S)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one(9-4)

[0214] [ka] (3R4S)-1-(4-methoxyphenyl)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one (9-3) (2.19 g, 6 mmol) was added dropwise to a solution of (30 ml) of acetonitrile (10.15 g, 18.5 mmol) of cerium(IV) ammonium nitrate aqueous solution over 30 minutes at 0°C. Then, H2O (35 ml) was added over 1 hour. After completion, the mixture was diluted with 200 ml of H2O and extracted with EA (200 ml). The organic phase was treated with saturated NaHCO3 (100 ml) and saturated NaHSO3 (100 ml), and again with saturated NaHCO3 (100 ml). Washed with brine, dried on anhydrous Na2SO4, and concentrated under vacuum. Next, the crude product was purified by silica gel column chromatography using EA:Hex (10:1~3:1) to obtain (3R4S)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one(9-4) as a colorless solid in 63% yield.

[0215] (3R4S)-1-Acryloyl-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one(9-5)

[0216] [ka] To a solution of (3R4S)-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one (9-4) (29.7 mg, 0.1 mmol) in dry CH2Cl2 (2 ml), Et3N (0.07 ml, 0.5 mmol) and 4-dimethylaminopyridine (12.2 mg, 0.1 mmol) were added under a nitrogen atmosphere at 0°C. Next, acryloyl chloride (27 mg, 0.3 mmol) was added. The mixture was stirred for 16 hours. After completion, 10 ml of EA was added, and the solvent was washed with saturated NH4Cl solvent, water, and brine. The organic phase was dried over anhydrous Na2SO4 and concentrated under vacuum. Next, the crude product was purified by silica gel column chromatography using EA:Hex (30:1~6:1) to obtain (3R4S)-1-acryloyl-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one (9-5) as a colorless oil in 62% yield.

[0217] 4-Methylbenzenesulfonate pento-4-en-1-yl(6)

[0218] [ka] To a pyridine solution (5 ml) of 4-en-1-ol (0.86 g, 10 mmol), 4-toluenesulfonyl chloride (4.19 g, 22 mmol) was added at 0°C. The mixture was stirred for 6 hours. After completion, 10 ml of EA was added, and the mixture was washed with 1 M HCl and 5% NaHCO3 to remove the pyridine. The organic phase was then treated with brine, dried over anhydrous Na2SO4, and concentrated under vacuum. The crude product was then purified by silica gel column using EA:Hex (20:1~4:1) to obtain pento-4-en-1-yl-4-methylbenzenesulfonate (9-6) as a colorless oil in 88% yield.

[0219] 5-Azidopent-1-En(9-7)

[0220] [ka] To a solution of pent-4-en-1-yl-4-methylbenzenesulfonate (9-6) (2.40 g, 10 mmol) in DMF (10 ml), sodium azide (1.05 g, 15 mmol) was added at room temperature. The mixture was stirred for 24 hours. After completion, the solution was rapidly cooled with H2O (30 ml) and then extracted with ether (10 ml x 3). The combined organic phase was treated with brine, dried over anhydrous Na2SO4, and slowly concentrated to remove the ether. The crude product was then used directly in the following steps.

[0221] Pent-4-ene-1-amine(9-8)

[0222] [ka] 5-Azidopentene-1-ene (9-7) (1.11 g, 10 mmol) in ether (10 ml) is heated at 0°C in a PPh solution. 3(2 Add 0.62g (10 mmol) of [unclear]. Stir for 1 hour. Next, add H2O (2 ml), warm the solution to room temperature, and stir for another 12 hours. After completion, rapidly cool the solution in ice water (10 ml) and mix the contents with CH2Cl2 (10 ml). * Extraction was performed in step 2). The combined organic phase was treated with brine, dried over anhydrous Na2SO4, and slowly concentrated to remove CH2Cl2. The crude product was then used directly in the following steps.

[0223] tert-butylpent-4-en-1-ylcarbamate (9-9)

[0224] [ka] To a solution of pent-4-en-1-amine (9-8) (0.85 g, 10 mmol) in CH2Cl2 (10 ml), Et3N (2.5 g, 25 mmol) and Boc-anhydrous (3.27 g, 15 mmol) were added at room temperature. The mixture was stirred for 6 hours. After completion, the solvent was washed with saturated NH4Cl, water, and brine. The organic phase was dried over anhydrous Na2SO4 and concentrated under vacuum. The crude product was then purified by silica gel column chromatography using EA:Hex (16:1~4:1) to obtain tert-butylpent-4-en-1-ylcarbamate (9-9) as a colorless oil in a total of 3 steps with a yield of 51%.

[0225] tert-butyl((tert-butoxycarbonyl)(pento-4-en-1-yl)carbamate(9-10)

[0226] [ka] 4-dimethylaminopyridine (0.24 g, 2 mmol) was added to acetonitrile solution (15 ml) of tert-butylpento-4-en-1-ylcarbamate (9-9) (1.85 g, 10 mmol). Boc-anhydride (2.4 g, 11 mmol) was then added at 50°C. The mixture was stirred for 24 hours. Boc-anhydride (1.2 g, 5.5 mmol) was then added, and the reaction was continued for another 24 hours. After completion, the solvent was removed under vacuum, and the mixture was directly purified by silica gel column chromatography using EA:Hex (20:1~5:1) to obtain tert-butyl(tert-butoxycarbonyl)(pento-4-en-1-yl)carbamate (9-10) as a colorless oil in 82% yield.

[0227] tert-butyl(tert-butoxycarbonyl)((E)-6-((2S,3R)-2-(2-methylprop-1-en-1-yl)-4-oxo-3-((triisopropylsilyl)oxy)azetidine-1-yl)-6-oxohexa-4-en-1-yl)carbamate(9-11)

[0228] [ka] To a solution of (3R4S)-1-acryloyl-4-(2-methylprop-1-en-1-yl)-3-((triisopropylsilyl)oxy)azetidine-2-one (9-5) (25 mg, 0.07 mmol) in CH2Cl2 (3 ml), tert-butyl(tert-butoxycarbonyl)(pento-4-en-1-yl)carbamate (9-10) (60.89 mg, 0.21 mmol) and Grubbs catalyst M720 (2 mg, 4% * 0.07 mmol) were added. The solvent was then heated to 50°C and the CH2Cl2 was refluxed. The mixture was stirred for 48 hours. After completion, the solvent was removed under vacuum, and the mixture was directly purified by silica gel column using EA:Hex (15:1~3:1) to obtain tert-butyl(tert-butoxycarbonyl)((E)-6-((2S,3R)-2-(2-methylprop-1-en-1-yl)-4-oxo-3-((triisopropylsilyl)oxy)azetidine-1-yl)-6-oxohexa-4-en-1-yl)carbamate (9-11) as a colorless oil in 91% yield.

[0229] (2aR4S,4aS,6R9S,11S,12S,12aR12bS)-12-(benzoyloxy)-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-12)

[0230] [ka] To a solution of 10-deacetylbaccatin (54.5 mg, 0.1 mmol) in THF (1 ml), cerium(III) chloride heptahydrate (1.86 mg, 0.005 mmol) was added, followed by the addition of acetic anhydride (1 ml, 1 mmol) at 0°C. The reaction slowly returned to room temperature. The mixture was stirred for 4 hours. After completion, it was rapidly cooled in ice water (10 ml) and ethyl acetate (2 ml) was added. *Extraction was performed using method 2). The combined organic phase was treated with brine, dried on anhydrous Na2SO4, and concentrated under vacuum. Next, the crude product was purified by silica gel column using EA:Hex (30:1~6:1) to obtain (2aR4S,4aS,6R9S,11S,12S,12aR12bS)-12-(benzoyloxy)-4,9,1-1trihydroxy-4a,8,13,13tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-12) as a white solid in 91% yield.

[0231] (2aR4S,4aS,6R9S,11S,12S)-12-(benzoyloxy)-9,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-13)

[0232] [ka] (2aR4S,4aS,6R9S,11S,12S,12aR12bS)-12-(benzoyloxy)-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-12) (0.293 g, 0.5 mmol) was dissolved in 5 ml of dry CH2Cl2, to which 4-dimethylaminopyridine (0.184 g, 1.5 mmol) was added under a nitrogen atmosphere. Chlorotriethylsilane (0.151 g, 1 mmol) was then added dropwise. The mixture was stirred at room temperature for 2 hours. After completion, it was treated with water and 1 M HCl. Next, the organic phase was washed with brine, dried on anhydrous Na2SO4, and concentrated under vacuum. The crude product was then purified by silica gel column chromatography using EA:Hex (4:1~1:1) to obtain (2aR4S,4aS,6R9S,11S,12S)-12-(benzoyloxy)-9,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiaacetate(9-13) as a white solid in 77% yield.

[0233] (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-5-methyl-2-((triisopropylsilyl)oxy)hex-4-enoyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-14)

[0234] [ka] (2aR4S,4aS,6R9S,11S,12S)-12-(benzoyloxy)-9,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiaacetate(9-13)(50mg, 0. A mixture of 0.0 (7 mmol) and tert-butyl (tert-butoxycarbonyl)((E)-6-((2S,3R)-2-(2-methylprop-1-en-1-yl)-4-oxo-3-((triisopropylsilyl)oxy)azetidine-1-yl)-6-oxohexa-4-en-1-yl)carbamate (9-11) (433 mg, 0.7 mmol) was mixed with dry THF (1 ml). The solvent was then cooled to -78°C. 1.0 M in THF (0.7 ml, 7 mmol) LiHMDS was added dropwise to the system and stirred for 1 hour. After completion, the solvent was directly quenched with saturated NH4Cl (5 ml), then washed with water and brine. Next, the crude product was purified by silica gel column using EA:Hex (4:1~1:1) to obtain (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-5 -Methyl-2-((triisopropylsilyl)oxy)hex-4-enoyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate (9-14) was obtained as a white solid in 89% yield.

[0235] (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-2-hydroxy-5-methylhex-4-enoyl)oxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-15)

[0236] [ka] (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-5-methyl-2-((triisopropylsilyl)oxy)hex-4-enoyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(((triethylsilyl)oxy)-3,4,4a,5,6,9,10, To a solution of 11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiaacetate(9-14) (50 mg, 0.038 mmol), 2 ml of HF / py in a 1:1 (v / v, pyridine:acetonitrile) ratio was added. The reaction was kept below 0°C (for a 7:3 ratio). The reaction mixture was then warmed to room temperature and stirred for 24 hours. After completion, the solvent was rapidly cooled directly with saturated NaHCO3 (5 ml), followed by ethyl acetate (10 ml). *Extraction was performed in step 2). The combined organic phase was washed with saturated copper sulfate (5 ml) and brine, dried over anhydrous Na2SO4, and concentrated under vacuum. Next, the crude product was purified by silica gel column using EA:Hex (4:1~1:1) to obtain (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-2-hydroxy-5-methylhex-4 -Enoyl)oxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9-15) was obtained as a white solid in 90% yield.

[0237] (2aR4S,4aS,6R9S,11S,12S)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(((((1R8S,9s)-bicyclo[6.1.0]non-4-in-9-yl)methoxy)carbonyl)amino)hexa-2-enamide)-2-hydroxy-5-methylhex-4-enoyl)oxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiaacetate(9-16)

[0238] [ka] (2aR4S,4aS,6R9S,11S,12aR,12bS)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(bis(tert-butoxycarbonyl)amino)hex-2-enamide)-2-hydroxy-5-methylhex-4-enoyl)oxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl To a solution of til-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiaacetate(9-15) (5 mg, 0.005 mmol) in CH2Cl2 (0.2 ml), 0.2 ml of TFA was added under a nitrogen atmosphere. The solvent was then stirred for 15 minutes. ESI showed that all compound 15 groups were dideprotected Boc groups. Next, CH2Cl2 and TFA were removed under vacuum. The residue was dissolved in 0.5 ml of DMF, and Et3N (0.1 ml) was added to adjust the pH to 8-9. ((1R8S,9s)-bicyclo[6.1.0]non-4-in-9-yl)methyl(4-nitrophenyl)carbonate (3 mg, 0.01 mmol) was added. The mixture was stirred for 24 hours. After completion, 2 ml of ethyl acetate was added and washed with water (2 ml * 3) and brine. The organic phase was dried on anhydrous Na2SO4 and concentrated under vacuum. Next, the crude product was purified by silica gel column using EA:Hex (3:1~1:1) and (2aR4S,4aS,6R9S,11S,12S)-12-(benzoyloxy)-9-(((2R3S)-3-((E)-6-(((((1R8S,9s)-bicyclo[6.1.0]non-4-in-9-yl)methoxy)carbonyl)amino)hexa-2-enamide)-2-hy Droxy-5-methylhex-4-enoyl)oxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12a-decahydro-1H-7,11-methanocyclodeca[3,4,]benzo[1,2-b]oxet-6,12b(2aH)-diyldiacetate(9,16) was obtained as a white solid.

[0239] Conjugate The clickable drug linkers (compounds 9-16) described above were conjugated to the Her2 antibody following the general procedure described in Example 4 above. Complete conversion of the modifications was observed by native intact IgG analysis (i.e., DAR=2).

[0240] The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as examples of some aspects of the claims, and functionally equivalent compositions and methods are intended to be included in the claims. In addition to those shown and described herein, various modifications of compositions and methods are intended to be included in the appended claims. Furthermore, although only certain representative compositions and method steps disclosed herein are specifically described, other combinations of compositions and method steps, even if not specifically described herein, are intended to be included in the appended claims. Accordingly, steps, elements, components, or combinations of components are included, whether expressly described herein or not, and other combinations of steps, elements, components, and components. The terms “includes” and its variations as used herein are used synonymously with “contains” and its variations and are open terms that are not limited. In this specification, the terms “includes” and “contains” have been used to describe various embodiments, but more specific embodiments of the invention can be provided and disclosed using the terms “essentially consist of” and “consist of” instead of “includes” and “contains.” Except as otherwise provided in the examples, all figures used in the specification and claims to represent amounts of components, reaction conditions, etc., are intended to be at least understandable and not to limit the application of the legal principles of the claims, so as to be interpreted in light of significant figures and common rounding methods.

[0241] Sequence listings, which are part of this specification.

[0242] [ka]

[0243]

change

[0244]

change

[0245]

change

Claims

1. The following formula: [[payload] x - Sialoside - Gal - GlcNAc] y - CBA (In the formula, CBA is a Her2 antibody; GlcNAc represents N-acetylglucosamine, which may be substituted with fucose in some cases; Gal represents galactose; Sialoside represents modified sialic acid; Each payload may be the same or different, as follows: 【Chemistry 1】 It is represented by; x is 1 or 2; and (y is either 1 or 2) A complex carbohydrate containing these properties.

2. The following formula: 【Chemistry 2】 (In the formula, R fa is a hydrogen or fucose portion; QQ is hydrogen, or the payload; ZZ is a hydroxyl group or the payload; YY is a hydroxyl group or the payload; XX is a hydroxyl group or the payload; and Here, at least one of QQ, ZZ, YY, and XX is the payload. The complex carbohydrate according to claim 1, represented as shown.

3. R fa The complex carbohydrate according to claim 2, wherein the fucose portion is the fucose portion.

4. R fa The structure is as follows: 【Transformation 3】 The complex carbohydrate according to claim 2, wherein the fucose portion has the fucose portion.

5. The complex carbohydrate according to claim 1, wherein GlcNAc is bound to the Her2 antibody via an asparagine side chain.

6. The complex carbohydrate according to claim 1, wherein GlcNAc is bound to at least one of the Asn297 residues of the Fc domain of the Her2 antibody.

7. The complex carbohydrate according to claim 1, wherein GlcNAc is bound to both Asn297 residues of the Fc domain of the Her2 antibody.

8. a) XX, YY, and ZZ are OH respectively; b) XX, YY are OH, and QQ are H; or c) XX, YY is OH The complex carbohydrate according to claim 2.

Citation Information

Patent Citations

  • Method for anti-molecule fixed point coupling and application

    CN107501388A

  • Antibody-drug conjugates

    US20180133340A1

  • Glycoprotein synthesis and remodeling by enzymatic transglycosylation

    WO2007133855A2

  • Modified antibody, antibody-conjugate and process for the preparation thereof

    WO2014065661A1

  • Pyrrolobenzodiazepine-antibody conjugates

    WO2018146189A1